{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T01:13:45Z","timestamp":1794100425453,"version":"4.8.0"},"reference-count":301,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Interv and Ther"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Primary Percutaneous Coronary Intervention (PCI) has significantly contributed to reducing the mortality of patients with ST segment elevation myocardial infarction (STEMI) even in cardiogenic shock and is now the standard of care in most of Japanese institutions. The Task Force on Primary PCI of the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT) proposed an expert consensus document for the management of acute myocardial infarction (AMI) focusing on procedural aspects of primary PCI in 2018 and updated in 2022 (Ozaki et al. in Cardiovasc Interv Ther 33:178\u2013203, 2018), (Ozaki et al. in Cardiovasc Interv Ther 37:1\u201334, 2022). Following the publication of the 2023 European Society of Cardiology (ESC) Guidelines for the management of acute coronary syndromes, the CVIT Task Force released another revised version in 2024 (Ozaki et al. in Cardiovasc Interv Ther 39:335\u2013375, 2024). In light of new clinical evidence and technological advances that have emerged since then, the Task Force now proposes an updated expert consensus document for the management of ACS focusing on procedural aspects of primary PCI in 2026 version.<\/jats:p>","DOI":"10.1007\/s12928-025-01229-z","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T18:50:57Z","timestamp":1772131857000},"page":"209-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2026"],"prefix":"10.1007","volume":"41","author":[{"given":"Yukio","family":"Ozaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Onuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Yamaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tevfik F.","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Kohsaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Morino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Shinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Ako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Yajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Shite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumi","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Shiode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsunori","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Hayashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruyasu","family":"Sugano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Okura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Okayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakazato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Suematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Hironaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Matoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Izawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Murohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Serruys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kozuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Task Force on Primary Percutaneous Coronary Intervention (PCI) of the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"1229_CR1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/nejm199908263410901","volume":"341","author":"JS Hochman","year":"1999","unstructured":"Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. New England J Med. 1999;341:625\u201334. https:\/\/doi.org\/10.1056\/nejm199908263410901.","journal-title":"New England J Med"},{"key":"1229_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/s0140-6736(02)09963-4","volume":"360","author":"E Bonnefoy","year":"2002","unstructured":"Bonnefoy E, Lapostolle F, Leizorovicz A, Steg G, McFadden EP, Dubien PY, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet. 2002;360:825\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(02)09963-4.","journal-title":"Lancet"},{"key":"1229_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S0195-668X(02)00468-2","volume":"24","author":"P Widimsky","year":"2003","unstructured":"Widimsky P, Budesinsky T, Vorac D, Groch L, Zelizko M, Aschermann M, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2. Eur Heart J. 2003;24:94\u2013104.","journal-title":"Eur Heart J"},{"key":"1229_CR4","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1161\/01.cir.0000103122.10021.f2","volume":"108","author":"PG Steg","year":"2003","unstructured":"Steg PG, Bonnefoy E, Chabaud S, Lapostolle F, Dubien PY, Cristofini P, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation. 2003;108:2851\u20136. https:\/\/doi.org\/10.1161\/01.cir.0000103122.10021.f2.","journal-title":"Circulation"},{"key":"1229_CR5","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1001\/jama.288.17.2130","volume":"288","author":"AM Lincoff","year":"2002","unstructured":"Lincoff AM, Califf RM, Van de Werf F, Willerson JT, White HD, Armstrong PW, et al. Mortality at 1 year with combination platelet glycoprotein IIb\/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA. 2002;288:2130\u20135.","journal-title":"JAMA"},{"key":"1229_CR6","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0735-1097(97)00018-1","volume":"29","author":"F Zijlstra","year":"1997","unstructured":"Zijlstra F, Beukema WP, van \u2019t Hof AW, Liem A, Reiffers S, Hoorntje JC, et al. Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction. J Am Coll Cardiol. 1997;29:908\u201312.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR7","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1056\/nejm199303113281002","volume":"328","author":"F Zijlstra","year":"1993","unstructured":"Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 1993;328:680\u20134. https:\/\/doi.org\/10.1056\/nejm199303113281002.","journal-title":"N Engl J Med"},{"key":"1229_CR8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1053\/euhj.1999.1993","volume":"21","author":"P Widimsky","year":"2000","unstructured":"Widimsky P, Groch L, Zelizko M, Aschermann M, Bednar F, Suryapranata H. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. PRAGUE Study Eur Heart J. 2000;21:823\u201331. https:\/\/doi.org\/10.1053\/euhj.1999.1993.","journal-title":"PRAGUE Study Eur Heart J"},{"key":"1229_CR9","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/S0735-1097(02)01878-8","volume":"39","author":"MJ de Boer","year":"2002","unstructured":"de Boer MJ, Ottervanger JP, van \u2019t Hof AW, Hoorntje JC, Suryapranata H, Zijlstra F. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol. 2002;39:1723\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/nejm199303113281001","volume":"328","author":"CL Grines","year":"1993","unstructured":"Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O\u2019Keefe J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The primary angioplasty in myocardial infarction study group. New England J Med. 1993;328:673\u20139. https:\/\/doi.org\/10.1056\/nejm199303113281001.","journal-title":"New England J Med"},{"key":"1229_CR11","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0735-1097(98)00446-X","volume":"32","author":"F Ribichini","year":"1998","unstructured":"Ribichini F, Steffenino G, Dellavalle A, Ferrero V, Vado A, Feola M, et al. Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression. J Am Coll Cardiol. 1998;32:1687\u201394.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0735-1097(98)00644-5","volume":"33","author":"E Garcia","year":"1999","unstructured":"Garcia E, Elizaga J, Perez-Castellano N, Serrano JA, Soriano J, Abeytua M, et al. Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. J Am College Cardiol. 1999;33:605\u201311.","journal-title":"J Am College Cardiol"},{"key":"1229_CR13","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/nejm199706053362301","volume":"336","author":"Investigators. GUoStOOCAiACSGIAS","year":"1997","unstructured":"Investigators. GUoStOOCAiACSGIAS. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1997;336:1621\u20138. https:\/\/doi.org\/10.1056\/nejm199706053362301.","journal-title":"N Engl J Med"},{"key":"1229_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1056\/nejm200008103430602","volume":"343","author":"A Schomig","year":"2000","unstructured":"Schomig A, Kastrati A, Dirschinger J, Mehilli J, Schricke U, Pache J, et al. Coronary stenting plus platelet glycoprotein IIb\/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med. 2000;343:385\u201391. https:\/\/doi.org\/10.1056\/nejm200008103430602.","journal-title":"N Engl J Med"},{"key":"1229_CR15","first-page":"426","volume":"82","author":"F Vermeer","year":"1999","unstructured":"Vermeer F, Oude Ophuis AJ, vd Berg EJ, Brunninkhuis LG, Werter CJ, Boehmer AG, et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart (British Cardiac Society). 1999;82:426\u201331.","journal-title":"Heart (British Cardiac Society)"},{"key":"1229_CR16","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/s0140-6736(02)08022-4","volume":"359","author":"A Kastrati","year":"2002","unstructured":"Kastrati A, Mehilli J, Dirschinger J, Schricke U, Neverve J, Pache J, et al. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. Lancet. 2002;359:920\u20135. https:\/\/doi.org\/10.1016\/s0140-6736(02)08022-4.","journal-title":"Lancet"},{"key":"1229_CR17","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1001\/jama.287.15.1943","volume":"287","author":"T Aversano","year":"2002","unstructured":"Aversano T, Aversano LT, Passamani E, Knatterud GL, Terrin ML, Williams DO, et al. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA. 2002;287:1943\u201351.","journal-title":"JAMA"},{"key":"1229_CR18","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/S0735-1097(02)01870-3","volume":"39","author":"CL Grines","year":"2002","unstructured":"Grines CL, Westerhausen DR Jr, Grines LL, Hanlon JT, Logemann TL, Niemela M, et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the air primary angioplasty in myocardial infarction study. J Am Coll Cardiol. 2002;39:1713\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJMoa025142","volume":"349","author":"HR Andersen","year":"2003","unstructured":"Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349:733\u201342. https:\/\/doi.org\/10.1056\/NEJMoa025142.","journal-title":"N Engl J Med"},{"key":"1229_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s12928-018-0516-y","volume":"33","author":"Y Ozaki","year":"2018","unstructured":"Ozaki Y, Katagiri Y, Onuma Y, Amano T, Muramatsu T, Kozuma K, et al. CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018. Cardiovasc Interv Ther. 2018;33:178\u2013203. https:\/\/doi.org\/10.1007\/s12928-018-0516-y.","journal-title":"Cardiovasc Interv Ther"},{"key":"1229_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12928-021-00829-9","volume":"37","author":"Y Ozaki","year":"2022","unstructured":"Ozaki Y, Hara H, Onuma Y, Katagiri Y, Amano T, Kobayashi Y, et al. CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022. Cardiovasc Interv Ther. 2022;37:1\u201334. https:\/\/doi.org\/10.1007\/s12928-021-00829-9.","journal-title":"Cardiovasc Interv Ther"},{"key":"1229_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39:119\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/ehx393.","journal-title":"Eur Heart J"},{"key":"1229_CR23","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289\u2013367. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa575.","journal-title":"Eur Heart J"},{"key":"1229_CR24","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720\u2013826. https:\/\/doi.org\/10.1093\/eurheartj\/ehad191.","journal-title":"Eur Heart J"},{"key":"1229_CR25","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s12928-024-01036-y","volume":"39","author":"Y Ozaki","year":"2024","unstructured":"Ozaki Y, Tobe A, Onuma Y, Kobayashi Y, Amano T, Muramatsu T, et al. CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2024. Cardiovasc Interv Ther. 2024;39:335\u201375. https:\/\/doi.org\/10.1007\/s12928-024-01036-y.","journal-title":"Cardiovasc Interv Ther"},{"key":"1229_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacasi.2021.12.005","volume":"2","author":"O Kwon","year":"2022","unstructured":"Kwon O, Park DW. Antithrombotic therapy after acute coronary syndromes or percutaneous coronary interventions in East Asian populations. JACC Asia. 2022;2:1\u201318. https:\/\/doi.org\/10.1016\/j.jacasi.2021.12.005.","journal-title":"JACC Asia"},{"key":"1229_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/clpt.2013.105","volume":"94","author":"SA Scott","year":"2013","unstructured":"Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94:317\u201323. https:\/\/doi.org\/10.1038\/clpt.2013.105.","journal-title":"Clin Pharmacol Ther"},{"key":"1229_CR28","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa2312572","volume":"390","author":"JE Moller","year":"2024","unstructured":"Moller JE, Engstrom T, Jensen LO, Eiskjaer H, Mangner N, Polzin A, et al. Microaxial flow pump or standard care in infarct-related cardiogenic shock. N Engl J Med. 2024;390:1382\u201393. https:\/\/doi.org\/10.1056\/NEJMoa2312572.","journal-title":"N Engl J Med"},{"key":"1229_CR29","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","volume":"33","author":"PG Steg","year":"2012","unstructured":"Steg PG, James SK, Atar D, Badano LP, Bl\u00f6mstrom-Lundqvist C, Borger MA, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569\u2013619. https:\/\/doi.org\/10.1093\/eurheartj\/ehs215.","journal-title":"Eur Heart J"},{"key":"1229_CR30","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jjcc.2023.01.008","volume":"81","author":"R Nishio","year":"2023","unstructured":"Nishio R, Ogita M, Suwa S, Nakao K, Ozaki Y, Kimura K, et al. Shorter door-to-balloon time, better long-term clinical outcomes in ST-segment elevation myocardial infarction patients: J-MINUET substudy. J Cardiol. 2023;81:564\u201370. https:\/\/doi.org\/10.1016\/j.jjcc.2023.01.008.","journal-title":"J Cardiol"},{"key":"1229_CR31","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1253\/circj.CJ-13-0174","volume":"77","author":"H Daida","year":"2013","unstructured":"Daida H, Miyauchi K, Ogawa H, Yokoi H, Matsumoto M, Kitakaze M, et al. Management and two-year long-term clinical outcome of acute coronary syndrome in Japan: prevention of atherothrombotic incidents following ischemic coronary attack (PACIFIC) registry. Circ J. 2013;77:934\u201343.","journal-title":"Circ J"},{"key":"1229_CR32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jacasi.2022.06.005","volume":"2","author":"H Miyachi","year":"2022","unstructured":"Miyachi H, Yamamoto T, Takayama M, Miyauchi K, Yamasaki M, Tanaka H, et al. 10-year temporal trends of in-hospital mortality and emergency percutaneous coronary intervention for acute myocardial infarction. JACC Asia. 2022;2:677\u201388. https:\/\/doi.org\/10.1016\/j.jacasi.2022.06.005.","journal-title":"JACC Asia"},{"key":"1229_CR33","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1253\/circj.CJ-22-0454","volume":"87","author":"K Fukui","year":"2023","unstructured":"Fukui K, Takahashi J, Hao K, Honda S, Nishihira K, Kojima S, et al. Disparity of performance measure by door-to-balloon time between a rural and urban area for management of patients with ST-segment elevation myocardial infarction - insights from the nationwide Japan Acute Myocardial Infarction Registry. Circ J. 2023;87:648\u201356. https:\/\/doi.org\/10.1253\/circj.CJ-22-0454.","journal-title":"Circ J"},{"key":"1229_CR34","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1253\/circj.CJ-23-0477","volume":"88","author":"R Arai","year":"2024","unstructured":"Arai R, Okumura Y, Murata N, Fukamachi D, Honda S, Nishihira K, et al. Prevalence and impact of polyvascular disease in patients with acute myocardial infarction in the contemporary era of percutaneous coronary intervention - insights from the Japan Acute Myocardial Infarction Registry (JAMIR). Circ J. 2024;88:911\u201320. https:\/\/doi.org\/10.1253\/circj.CJ-23-0477.","journal-title":"Circ J"},{"key":"1229_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeab047","volume":"2","author":"M Ishii","year":"2022","unstructured":"Ishii M, Tsujita K, Okamoto H, Koto S, Nishi T, Nakai M, et al. Resources for cardiovascular healthcare associated with 30-day mortality in acute myocardial infarction with cardiogenic shock. Eur Heart J Open. 2022;2:oeab047. https:\/\/doi.org\/10.1093\/ehjopen\/oeab047.","journal-title":"Eur Heart J Open"},{"key":"1229_CR36","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/ccd.30457","volume":"100","author":"F Anzai","year":"2022","unstructured":"Anzai F, Yoshihisa A, Takeishi R, Hotsuki Y, Sato Y, Sumita Y, et al. Acute myocardial infarction caused by Kawasaki disease requires more intensive therapy: insights from the Japanese registry of all cardiac and vascular diseases-diagnosis Procedure combination. Catheter Cardiovasc Interv. 2022;100:1173\u201381. https:\/\/doi.org\/10.1002\/ccd.30457.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1229_CR37","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023713","volume":"11","author":"T Nishi","year":"2022","unstructured":"Nishi T, Ishii M, Tsujita K, Okamoto H, Koto S, Nakai M, et al. Outcomes of venoarterial extracorporeal membrane oxygenation plus intra-aortic balloon pumping for treatment of acute myocardial infarction complicated by cardiogenic shock. J Am Heart Assoc. 2022;11:e023713. https:\/\/doi.org\/10.1161\/JAHA.121.023713.","journal-title":"J Am Heart Assoc"},{"key":"1229_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100434","volume":"22","author":"K Yamaji","year":"2022","unstructured":"Yamaji K, Kohsaka S, Inohara T, Numasawa Y, Ando H, Wada H, et al. Percutaneous coronary intervention during the COVID-19 pandemic in Japan: insights from the nationwide registration data. Lancet Regional Health Western Pacific. 2022;22:100434. https:\/\/doi.org\/10.1016\/j.lanwpc.2022.100434.","journal-title":"Lancet Regional Health Western Pacific"},{"key":"1229_CR39","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.025728","volume":"11","author":"T Inohara","year":"2022","unstructured":"Inohara T, Kohsaka S, Yamaji K, Iida O, Shinke T, Sakakura K, et al. Use of thrombus aspiration for patients with acute coronary syndrome: insights from the nationwide J-PCI registry. J Am Heart Assoc. 2022;11:e025728. https:\/\/doi.org\/10.1161\/JAHA.122.025728.","journal-title":"J Am Heart Assoc"},{"key":"1229_CR40","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jacasi.2022.03.013","volume":"2","author":"H Ando","year":"2022","unstructured":"Ando H, Yamaji K, Kohsaka S, Ishii H, Sakakura K, Goto R, et al. Clinical presentation and in-hospital outcomes of acute myocardial infarction in young patients: Japanese nationwide registry. JACC Asia. 2022;2:574\u201385. https:\/\/doi.org\/10.1016\/j.jacasi.2022.03.013.","journal-title":"JACC Asia"},{"key":"1229_CR41","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.amjcard.2023.01.027","volume":"192","author":"Y Saito","year":"2023","unstructured":"Saito Y, Inohara T, Kohsaka S, Ando H, Ishii H, Yamaji K, et al. Volume-outcome relations of percutaneous coronary intervention in patients presenting with acute myocardial infarction (from the J-PCI Registry). Am J Cardiol. 2023;192:182\u20139. https:\/\/doi.org\/10.1016\/j.amjcard.2023.01.027.","journal-title":"Am J Cardiol"},{"key":"1229_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ahj.2023.01.009","volume":"258","author":"Y Saito","year":"2023","unstructured":"Saito Y, Inohara T, Kohsaka S, Wada H, Takamisawa I, Yamaji K, et al. Characteristics and outcomes of patients with no standard modifiable risk factors undergoing primary revascularization for acute myocardial infarction: insights from the nationwide Japanese percutaneous coronary intervention registry. Am Heart J. 2023;258:69\u201376. https:\/\/doi.org\/10.1016\/j.ahj.2023.01.009.","journal-title":"Am Heart J"},{"key":"1229_CR43","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0140-6736(20)31356-8","volume":"396","author":"MM Mafham","year":"2020","unstructured":"Mafham MM, Spata E, Goldacre R, Gair D, Curnow P, Bray M, et al. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet. 2020;396:381\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(20)31356-8.","journal-title":"Lancet"},{"key":"1229_CR44","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1056\/NEJMc2015630","volume":"383","author":"MD Solomon","year":"2020","unstructured":"Solomon MD, McNulty EJ, Rana JS, Leong TK, Lee C, Sung SH, et al. The COVID-19 pandemic and the incidence of acute myocardial infarction. N Engl J Med. 2020;383:691\u20133. https:\/\/doi.org\/10.1056\/NEJMc2015630.","journal-title":"N Engl J Med"},{"key":"1229_CR45","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.jacc.2021.07.039","volume":"78","author":"F Bouisset","year":"2021","unstructured":"Bouisset F, Gerbaud E, Bataille V, Coste P, Puymirat E, Belle L, et al. Percutaneous myocardial revascularization in late-presenting patients with STEMI. J Am Coll Cardiol. 2021;78:1291\u2013305. https:\/\/doi.org\/10.1016\/j.jacc.2021.07.039.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR46","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa066139","volume":"355","author":"JS Hochman","year":"2006","unstructured":"Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355:2395\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa066139.","journal-title":"N Engl J Med"},{"key":"1229_CR47","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1016\/j.jacc.2010.03.007","volume":"55","author":"KA Fox","year":"2010","unstructured":"Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JG, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol. 2010;55:2435\u201345. https:\/\/doi.org\/10.1016\/j.jacc.2010.03.007.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR48","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa2407791","volume":"391","author":"V Kunadian","year":"2024","unstructured":"Kunadian V, Mossop H, Shields C, Bardgett M, Watts P, Teare MD, et al. Invasive treatment strategy for older patients with myocardial infarction. N Engl J Med. 2024;391:1673\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2407791.","journal-title":"N Engl J Med"},{"key":"1229_CR49","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1161\/circulationaha.118.037152","volume":"138","author":"KF Kofoed","year":"2018","unstructured":"Kofoed KF, Kelb\u00e6k H, Hansen PR, Torp-Pedersen C, H\u00f8fsten D, Kl\u00f8vgaard L, et al. Early versus standard care invasive examination and treatment of patients with non-ST-segment elevation acute coronary syndrome. Circulation. 2018;138:2741\u201350. https:\/\/doi.org\/10.1161\/circulationaha.118.037152.","journal-title":"Circulation"},{"key":"1229_CR50","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jjcc.2017.09.006","volume":"71","author":"K Komiyama","year":"2018","unstructured":"Komiyama K, Nakamura M, Tanabe K, Niikura H, Fujimoto H, Oikawa K, et al. In-hospital mortality analysis of Japanese patients with acute coronary syndrome using the Tokyo CCU Network database: applicability of the GRACE risk score. J Cardiol. 2018;71:251\u20138. https:\/\/doi.org\/10.1016\/j.jjcc.2017.09.006.","journal-title":"J Cardiol"},{"key":"1229_CR51","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1253\/circj.CJ-20-1115","volume":"85","author":"Y Hashimoto","year":"2021","unstructured":"Hashimoto Y, Ozaki Y, Kan S, Nakao K, Kimura K, Ako J, et al. Impact of chronic kidney disease on in-hospital and 3-year clinical outcomes in patients with acute myocardial infarction treated by contemporary percutaneous coronary intervention and optimal medical therapy - insights from the J-MINUET study. Circ J. 2021;85:1710\u20138. https:\/\/doi.org\/10.1253\/circj.CJ-20-1115.","journal-title":"Circ J"},{"key":"1229_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2017.09.006","author":"K Komiyama","year":"2017","unstructured":"Komiyama K, Nakamura M, Tanabe K, Niikura H, Fujimoto H, Oikawa K, et al. In-hospital mortality analysis of Japanese patients with acute coronary syndrome using the Tokyo CCU Network database: Applicability of the GRACE risk score. J Cardiol. 2017. https:\/\/doi.org\/10.1016\/j.jjcc.2017.09.006.","journal-title":"J Cardiol"},{"key":"1229_CR53","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa1816897","volume":"380","author":"JS Lemkes","year":"2019","unstructured":"Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA, Meuwissen M, et al. Coronary angiography after cardiac arrest without ST-segment elevation. N Engl J Med. 2019;380:1397\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa1816897.","journal-title":"N Engl J Med"},{"key":"1229_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamacardio.2020.3670","volume":"5","author":"JS Lemkes","year":"2020","unstructured":"Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA, Meuwissen MM, et al. Coronary angiography after cardiac arrest without ST segment elevation: one-year outcomes of the COACT randomized clinical trial. JAMA Cardiol. 2020;5:1\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2020.3670.","journal-title":"JAMA Cardiol"},{"key":"1229_CR55","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1056\/NEJMoa2101909","volume":"385","author":"S Desch","year":"2021","unstructured":"Desch S, Freund A, Akin I, Behnes M, Preusch MR, Zelniker TA, et al. Angiography after out-of-hospital cardiac arrest without ST-segment elevation. N Engl J Med. 2021;385:2544\u201353. https:\/\/doi.org\/10.1056\/NEJMoa2101909.","journal-title":"N Engl J Med"},{"key":"1229_CR56","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamacardio.2023.2264","volume":"8","author":"S Desch","year":"2023","unstructured":"Desch S, Freund A, Akin I, Behnes M, Preusch MR, Zelniker TA, et al. Coronary angiography after out-of-hospital cardiac arrest without ST-segment elevation: one-year outcomes of a randomized clinical trial. JAMA Cardiol. 2023;8:827\u201334. https:\/\/doi.org\/10.1001\/jamacardio.2023.2264.","journal-title":"JAMA Cardiol"},{"key":"1229_CR57","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamacardio.2022.1416","volume":"7","author":"C Hauw-Berlemont","year":"2022","unstructured":"Hauw-Berlemont C, Lamhaut L, Diehl JL, Andreotti C, Varenne O, Leroux P, et al. Emergency vs delayed coronary angiogram in survivors of out-of-hospital cardiac arrest: results of the randomized, multicentric EMERGE trial. JAMA Cardiol. 2022;7:700\u20137. https:\/\/doi.org\/10.1001\/jamacardio.2022.1416.","journal-title":"JAMA Cardiol"},{"key":"1229_CR58","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001\u201315. https:\/\/doi.org\/10.1056\/NEJMoa0706482.","journal-title":"N Engl J Med"},{"key":"1229_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx393","author":"B Ibanez","year":"2017","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017. https:\/\/doi.org\/10.1093\/eurheartj\/ehx393.","journal-title":"Eur Heart J"},{"key":"1229_CR60","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1253\/circj.cj-13-1482","volume":"78","author":"S Saito","year":"2014","unstructured":"Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J. 2014;78:1684\u201392. https:\/\/doi.org\/10.1253\/circj.cj-13-1482.","journal-title":"Circ J"},{"key":"1229_CR61","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1093\/eurheartj\/ehw284","volume":"37","author":"A Sahlen","year":"2016","unstructured":"Sahlen A, Varenhorst C, Lagerqvist B, Renlund H, Omerovic E, Erlinge D, et al. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. Eur Heart J. 2016;37:3335\u201342. https:\/\/doi.org\/10.1093\/eurheartj\/ehw284.","journal-title":"Eur Heart J"},{"key":"1229_CR62","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0904327.","journal-title":"N Engl J Med"},{"key":"1229_CR63","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","volume":"381","author":"S Schupke","year":"2019","unstructured":"Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381:1524\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1908973.","journal-title":"N Engl J Med"},{"key":"1229_CR64","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/s0140-6736(11)60876-3","volume":"378","author":"G Montalescot","year":"2011","unstructured":"Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet. 2011;378:693\u2013703. https:\/\/doi.org\/10.1016\/s0140-6736(11)60876-3.","journal-title":"Lancet"},{"key":"1229_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e553","volume":"344","author":"J Silvain","year":"2012","unstructured":"Silvain J, Beygui F, Barthelemy O, Pollack C Jr., Cohen M, Zeymer U, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012;344:e553. https:\/\/doi.org\/10.1136\/bmj.e553.","journal-title":"BMJ"},{"key":"1229_CR66","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/2048872615572599","volume":"5","author":"D Capodanno","year":"2016","unstructured":"Capodanno D, Gargiulo G, Capranzano P, Mehran R, Tamburino C, Stone GW. Bivalirudin versus heparin with or without glycoprotein IIb\/IIIa inhibitors in patients with STEMI undergoing primary PCI: an updated meta-analysis of 10,350 patients from five randomized clinical trials. Eur Heart J Acute Cardiovasc Care. 2016;5:253\u201362. https:\/\/doi.org\/10.1177\/2048872615572599.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"1229_CR67","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1507854","volume":"373","author":"M Valgimigli","year":"2015","unstructured":"Valgimigli M, Frigoli E, Leonardi S, Rothenbuhler M, Gagnor A, Calabro P, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med. 2015;373:997\u20131009. https:\/\/doi.org\/10.1056\/NEJMoa1507854.","journal-title":"N Engl J Med"},{"key":"1229_CR68","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","volume":"358","author":"GW Stone","year":"2008","unstructured":"Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218\u201330. https:\/\/doi.org\/10.1056\/NEJMoa0708191.","journal-title":"N Engl J Med"},{"key":"1229_CR69","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1056\/NEJMoa0802944","volume":"359","author":"A Kastrati","year":"2008","unstructured":"Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359:688\u201396. https:\/\/doi.org\/10.1056\/NEJMoa0802944.","journal-title":"N Engl J Med"},{"key":"1229_CR70","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.amjcard.2009.08.668","volume":"105","author":"G Ndrepepa","year":"2010","unstructured":"Ndrepepa G, Schulz S, Keta D, Mehilli J, Birkmeier A, Massberg S, et al. Bleeding after percutaneous coronary intervention with bivalirudin or unfractionated heparin and one-year mortality. Am J Cardiol. 2010;105:163\u20137. https:\/\/doi.org\/10.1016\/j.amjcard.2009.08.668.","journal-title":"Am J Cardiol"},{"key":"1229_CR71","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","volume":"377","author":"D Erlinge","year":"2017","unstructured":"Erlinge D, Omerovic E, Frobert O, Linder R, Danielewicz M, Hamid M, et al. Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med. 2017;377:1132\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1706443.","journal-title":"N Engl J Med"},{"key":"1229_CR72","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1253\/circj.CJ-08-0560","volume":"73","author":"Y Nakagawa","year":"2009","unstructured":"Nakagawa Y, Nobuyoshi M, Yamaguchi T, Meguro T, Yokoi H, Kimura T, et al. Efficacy of abciximab for patients undergoing balloon angioplasty: data from Japanese evaluation of c7E3 Fab for elective and primary PCI organization in randomized trial (JEPPORT). Circ J. 2009;73:145\u201351.","journal-title":"Circ J"},{"key":"1229_CR73","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1161\/CIRCULATIONAHA.123.067079","volume":"149","author":"Y Yan","year":"2024","unstructured":"Yan Y, Guo J, Wang X, Wang G, Fan Z, Yin D, et al. Postprocedural anticoagulation after primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction: a multicenter, randomized, double-blind trial. Circulation. 2024;149:1258\u201367. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067079.","journal-title":"Circulation"},{"key":"1229_CR74","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/j.jacc.2012.06.017","volume":"60","author":"E Romagnoli","year":"2012","unstructured":"Romagnoli E, Biondi-Zoccai G, Sciahbasi A, Politi L, Rigattieri S, Pendenza G, et al. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial versus femoral randomized investigation in ST-elevation acute coronary syndrome) study. J Am Coll Cardiol. 2012;60:2481\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2012.06.017.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR75","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/s0140-6736(11)60404-2","volume":"377","author":"SS Jolly","year":"2011","unstructured":"Jolly SS, Yusuf S, Cairns J, Niemela K, Xavier D, Widimsky P, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011;377:1409\u201320. https:\/\/doi.org\/10.1016\/s0140-6736(11)60404-2.","journal-title":"Lancet"},{"key":"1229_CR76","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/eurheartj\/ehx048","volume":"38","author":"P Vranckx","year":"2017","unstructured":"Vranckx P, Frigoli E, Rothenbuhler M, Tomassini F, Garducci S, Ando G, et al. Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. Eur Heart J. 2017;38:1069\u201380. https:\/\/doi.org\/10.1093\/eurheartj\/ehx048.","journal-title":"Eur Heart J"},{"key":"1229_CR77","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1001\/jamacardio.2019.4852","volume":"5","author":"M Le May","year":"2020","unstructured":"Le May M, Wells G, So D, Chong AY, Dick A, Froeschl M, et al. Safety and efficacy of femoral access vs radial access in ST-segment elevation myocardial infarction: the SAFARI-STEMI randomized clinical trial. JAMA Cardiol. 2020;5:126\u201334. https:\/\/doi.org\/10.1001\/jamacardio.2019.4852.","journal-title":"JAMA Cardiol"},{"key":"1229_CR78","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/ccd.10493","volume":"59","author":"S Saito","year":"2003","unstructured":"Saito S, Tanaka S, Hiroe Y, Miyashita Y, Takahashi S, Tanaka K, et al. Comparative study on transradial approach vs. transfemoral approach in primary stent implantation for patients with acute myocardial infarction: results of the test for myocardial infarction by prospective unicenter randomization for access sites (TEMPURA) trial. Catheter Cardiovasc Interv. 2003;59:26\u201333. https:\/\/doi.org\/10.1002\/ccd.10493.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1229_CR79","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1253\/circj.CJ-15-0276","volume":"79","author":"S Saito","year":"2015","unstructured":"Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nishikawa M, et al. Impact of arterial access route on bleeding complications in Japanese patients undergoing percutaneous coronary intervention- insight from the PRASFIT trial. Circ J. 2015;79:1928\u201337. https:\/\/doi.org\/10.1253\/circj.CJ-15-0276.","journal-title":"Circ J"},{"key":"1229_CR80","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1007\/s00380-017-1021-4","volume":"32","author":"Y Yamashita","year":"2017","unstructured":"Yamashita Y, Shiomi H, Morimoto T, Yaku H, Kaji S, Furukawa Y, et al. Transradial versus transfemoral approach in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction: insight from the CREDO-Kyoto AMI registry. Heart Vessels. 2017;32:1448\u201357. https:\/\/doi.org\/10.1007\/s00380-017-1021-4.","journal-title":"Heart Vessels"},{"key":"1229_CR81","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.ehj.2004.01.002","volume":"25","author":"JA Schaar","year":"2004","unstructured":"Schaar JA, Muller JE, Falk E, Virmani R, Fuster V, Serruys PW, et al. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini Greece. Eur Heart J. 2004;25:1077\u201382. https:\/\/doi.org\/10.1016\/j.ehj.2004.01.002.","journal-title":"Eur Heart J"},{"key":"1229_CR82","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1136\/hrt.82.3.269","volume":"82","author":"E Arbustini","year":"1999","unstructured":"Arbustini E, Dal Bello B, Morbini P, Burke AP, Bocciarelli M, Specchia G, et al. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart. 1999;82:269\u201372. https:\/\/doi.org\/10.1136\/hrt.82.3.269.","journal-title":"Heart"},{"key":"1229_CR83","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.jacc.2013.05.071","volume":"62","author":"H Jia","year":"2013","unstructured":"Jia H, Abtahian F, Aguirre AD, Lee S, Chia S, Lowe H, et al. In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. J Am Coll Cardiol. 2013;62:1748\u201358. https:\/\/doi.org\/10.1016\/j.jacc.2013.05.071.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR84","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1093\/eurheartj\/ehr189","volume":"32","author":"Y Ozaki","year":"2011","unstructured":"Ozaki Y, Okumura M, Ismail TF, Motoyama S, Naruse H, Hattori K, et al. Coronary CT angiographic characteristics of culprit lesions in acute coronary syndromes not related to plaque rupture as defined by optical coherence tomography and angioscopy. Eur Heart J. 2011;32:2814\u201323. https:\/\/doi.org\/10.1093\/eurheartj\/ehr189.","journal-title":"Eur Heart J"},{"key":"1229_CR85","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jacc.2007.04.082","volume":"50","author":"T Kubo","year":"2007","unstructured":"Kubo T, Imanishi T, Takarada S, Kuroi A, Ueno S, Yamano T, et al. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol. 2007;50:933\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2007.04.082.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR86","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/s0140-6736(17)30057-0","volume":"389","author":"EC Nijssen","year":"2017","unstructured":"Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017;389:1312\u201322. https:\/\/doi.org\/10.1016\/s0140-6736(17)30057-0.","journal-title":"Lancet"},{"key":"1229_CR87","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1161\/circulationaha.116.025371","volume":"135","author":"SS Jolly","year":"2017","unstructured":"Jolly SS, James S, Dzavik V, Cairns JA, Mahmoud KD, Zijlstra F, et al. Thrombus aspiration in ST-segment-elevation myocardial infarction: an individual patient meta-analysis: thrombectomy trialists collaboration. Circulation. 2017;135:143\u201352. https:\/\/doi.org\/10.1161\/circulationaha.116.025371.","journal-title":"Circulation"},{"key":"1229_CR88","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1056\/NEJMoa0706416","volume":"358","author":"T Svilaas","year":"2008","unstructured":"Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358:557\u201367. https:\/\/doi.org\/10.1056\/NEJMoa0706416.","journal-title":"N Engl J Med"},{"key":"1229_CR89","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1093\/eurheartj\/ehp348","volume":"30","author":"F Burzotta","year":"2009","unstructured":"Burzotta F, De Vita M, Gu YL, Isshiki T, Lefevre T, Kaltoft A, et al. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. Eur Heart J. 2009;30:2193\u2013203. https:\/\/doi.org\/10.1093\/eurheartj\/ehp348.","journal-title":"Eur Heart J"},{"key":"1229_CR90","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jcin.2008.06.004","volume":"1","author":"Y Ikari","year":"2008","unstructured":"Ikari Y, Sakurada M, Kozuma K, Kawano S, Katsuki T, Kimura K, et al. Upfront thrombus aspiration in primary coronary intervention for patients with ST-segment elevation acute myocardial infarction: report of the VAMPIRE (VAcuuM asPIration thrombus REmoval) trial. JACC Cardiovasc Interv. 2008;1:424\u201331. https:\/\/doi.org\/10.1016\/j.jcin.2008.06.004.","journal-title":"JACC Cardiovasc Interv"},{"key":"1229_CR91","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.amjcard.2007.05.040","volume":"100","author":"D Nakatani","year":"2007","unstructured":"Nakatani D, Sato H, Sakata Y, Mizuno H, Shimizu M, Suna S, et al. Effect of intracoronary thrombectomy on 30-day mortality in patients with acute myocardial infarction. Am J Cardiol. 2007;100:1212\u20137. https:\/\/doi.org\/10.1016\/j.amjcard.2007.05.040.","journal-title":"Am J Cardiol"},{"key":"1229_CR92","first-page":"487","volume":"2","author":"H Hara","year":"2007","unstructured":"Hara H, Nakamura M, Komatsu H, Ikeda N, Shinji H, Makino K, et al. Comparison of the in vitro performance of 6 and 7 French aspiration catheters. EuroInterv J EuroPCR Collab Working Group Interv Cardiol Eur Soc Cardiol. 2007;2:487\u201392.","journal-title":"EuroInterv J EuroPCR Collab Working Group Interv Cardiol Eur Soc Cardiol"},{"key":"1229_CR93","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1253\/circj.67.768","volume":"67","author":"H Anzai","year":"2003","unstructured":"Anzai H, Yoneyama S, Tsukagoshi M, Miyake T, Kikuchi T, Sakurada M. Rescue percutaneous thrombectomy system provides better angiographic coronary flow and does not increase the in-hospital cost in patients with acute myocardial infarction. Circ J. 2003;67:768\u201374.","journal-title":"Circ J"},{"key":"1229_CR94","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jama.293.9.1063","volume":"293","author":"GW Stone","year":"2005","unstructured":"Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA. 2005;293:1063\u201372. https:\/\/doi.org\/10.1001\/jama.293.9.1063.","journal-title":"JAMA"},{"key":"1229_CR95","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1093\/eurheartj\/ehn421","volume":"29","author":"AA Bavry","year":"2008","unstructured":"Bavry AA, Kumbhani DJ, Bhatt DL. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials. Eur Heart J. 2008;29:2989\u20133001. https:\/\/doi.org\/10.1093\/eurheartj\/ehn421.","journal-title":"Eur Heart J"},{"key":"1229_CR96","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s12928-010-0027-y","volume":"26","author":"T Isshiki","year":"2011","unstructured":"Isshiki T, Kozuma K, Kyono H, Suzuki N, Yokoyama N, Yamamoto Y. Initial clinical experience with distal embolic protection using \u201cFiltrap\u201d, a novel filter device with a self-expandable spiral basket in patients undergoing percutaneous coronary intervention. Cardiovasc Interv Ther. 2011;26:12\u20137. https:\/\/doi.org\/10.1007\/s12928-010-0027-y.","journal-title":"Cardiovasc Interv Ther"},{"key":"1229_CR97","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/ccd.21190","volume":"70","author":"T Muramatsu","year":"2007","unstructured":"Muramatsu T, Kozuma K, Tsukahara R, Ito Y, Fujita N, Suwa S, et al. Comparison of myocardial perfusion by distal protection before and after primary stenting for acute myocardial infarction: angiographic and clinical results of a randomized controlled trial. Catheter Cardiovasc Interv. 2007;70:677\u201382. https:\/\/doi.org\/10.1002\/ccd.21190.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1229_CR98","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jcin.2015.01.032","volume":"8","author":"GW Stone","year":"2015","unstructured":"Stone GW, Maehara A, Muller JE, Rizik DG, Shunk KA, Ben-Yehuda O, et al. Plaque characterization to inform the prediction and prevention of periprocedural myocardial infarction during percutaneous coronary intervention: The CANARY trial (Coronary assessment by near-infrared of atherosclerotic rupture-prone yellow). JACC Cardiovasc Interv. 2015;8:927\u201336. https:\/\/doi.org\/10.1016\/j.jcin.2015.01.032.","journal-title":"JACC Cardiovasc Interv"},{"key":"1229_CR99","unstructured":"Hibi K, Kozuma K, Sonoda S, Endo T, Tanaka H, Kyono H, Koshida R, Ishihara T, Awata M, Kume T, et al. Distal Filter Protection Versus Conventional Treatment during PCI in Patients with Attenuated Plaque Identified by IVUS: VAcuuM asPIration thrombus Removal (VAMPIRE) 3 trial. Presented at TCT 2017."},{"key":"1229_CR100","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1161\/01.CIR.0000012783.63093.0C","volume":"105","author":"DS Baim","year":"2002","unstructured":"Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 2002;105:1285\u201390.","journal-title":"Circulation"},{"key":"1229_CR101","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1161\/circulationaha.104.530329","volume":"112","author":"H Ishii","year":"2005","unstructured":"Ishii H, Ichimiya S, Kanashiro M, Amano T, Imai K, Murohara T, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation. 2005;112:1284\u20138. https:\/\/doi.org\/10.1161\/circulationaha.104.530329.","journal-title":"Circulation"},{"key":"1229_CR102","first-page":"211","volume":"2","author":"A Miyazawa","year":"2006","unstructured":"Miyazawa A, Ikari Y, Tanabe K, Nakajima H, Aoki J, Iijima R, et al. Intracoronary nicorandil prior to reperfusion in acute myocardial infarction. EuroIntervent J EuroPCR Collab Working Group Interv Cardiol Eur Soc Cardiol. 2006;2:211\u20137.","journal-title":"EuroIntervent J EuroPCR Collab Working Group Interv Cardiol Eur Soc Cardiol"},{"key":"1229_CR103","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00380-010-0065-5","volume":"26","author":"R Kobatake","year":"2011","unstructured":"Kobatake R, Sato T, Fujiwara Y, Sunami H, Yoshioka R, Ikeda T, et al. Comparison of the effects of nitroprusside versus nicorandil on the slow\/no-reflow phenomenon during coronary interventions for acute myocardial infarction. Heart Vessels. 2011;26:379\u201384. https:\/\/doi.org\/10.1007\/s00380-010-0065-5.","journal-title":"Heart Vessels"},{"key":"1229_CR104","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12872-017-0722-z","volume":"18","author":"X Niu","year":"2018","unstructured":"Niu X, Zhang J, Bai M, Peng Y, Sun S, Zhang Z. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis. BMC Cardiovasc Disord. 2018;18:3. https:\/\/doi.org\/10.1186\/s12872-017-0722-z.","journal-title":"BMC Cardiovasc Disord"},{"key":"1229_CR105","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4244\/eijv12i3a52","volume":"12","author":"G Ndrepepa","year":"2016","unstructured":"Ndrepepa G, Kastrati A. Mechanical strategies to enhance myocardial salvage during primary percutaneous coronary intervention in patients with STEMI. EuroIntervention. 2016;12:319\u201328. https:\/\/doi.org\/10.4244\/eijv12i3a52.","journal-title":"EuroIntervention"},{"key":"1229_CR106","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0735-1097(01)01701-6","volume":"39","author":"C Loubeyre","year":"2002","unstructured":"Loubeyre C, Morice MC, Lefevre T, Piechaud JF, Louvard Y, Dumas P. A randomized comparison of direct stenting with conventional stent implantation in selected patients with acute myocardial infarction. J Am Coll Cardiol. 2002;39:15\u201321.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR107","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/j.amjcard.2011.07.040","volume":"108","author":"M Mockel","year":"2011","unstructured":"Mockel M, Vollert J, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, et al. Comparison of direct stenting with conventional stent implantation in acute myocardial infarction. Am J Cardiol. 2011;108:1697\u2013703. https:\/\/doi.org\/10.1016\/j.amjcard.2011.07.040.","journal-title":"Am J Cardiol"},{"key":"1229_CR108","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/ccd.25266","volume":"84","author":"A Dziewierz","year":"2014","unstructured":"Dziewierz A, Siudak Z, Rakowski T, Kleczynski P, Zasada W, Dubiel JS, et al. Impact of direct stenting on outcome of patients with ST-elevation myocardial infarction transferred for primary percutaneous coronary intervention (from the EUROTRANSFER registry). Catheter Cardiovasc Interv. 2014;84:925\u201331. https:\/\/doi.org\/10.1002\/ccd.25266.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1229_CR109","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0195-668X(02)00802-3","volume":"24","author":"E Barbato","year":"2003","unstructured":"Barbato E, Marco J, Wijns W. Direct stenting. Eur Heart J. 2003;24:394\u2013403.","journal-title":"Eur Heart J"},{"key":"1229_CR110","first-page":"316","volume":"2","author":"GS Mintz","year":"2000","unstructured":"Mintz GS. Remodeling and restenosis: observations from serial intravascular ultrasound studies. Curr Interv Cardiol Rep. 2000;2:316\u201325.","journal-title":"Curr Interv Cardiol Rep"},{"key":"1229_CR111","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0002-9149(01)01645-9","volume":"88","author":"MM Zhu","year":"2001","unstructured":"Zhu MM, Feit A, Chadow H, Alam M, Kwan T, Clark LT. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol. 2001;88:297\u2013301.","journal-title":"Am J Cardiol"},{"key":"1229_CR112","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijcard.2007.03.112","volume":"126","author":"G De Luca","year":"2008","unstructured":"De Luca G, Suryapranata H, Stone GW, Antoniucci D, Biondi-Zoccai G, Kastrati A, et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. Int J Cardiol. 2008;126:37\u201344. https:\/\/doi.org\/10.1016\/j.ijcard.2007.03.112.","journal-title":"Int J Cardiol"},{"key":"1229_CR113","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1136\/hrt.2004.056705","volume":"91","author":"H Suryapranata","year":"2005","unstructured":"Suryapranata H, De Luca G, van \u2019t Hof AW, Ottervanger JP, Hoorntje JC, Dambrink JH, et al. Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients. Heart. 2005;91:641\u20135. https:\/\/doi.org\/10.1136\/hrt.2004.056705.","journal-title":"Heart"},{"key":"1229_CR114","first-page":"262","volume":"48","author":"S Saito","year":"1999","unstructured":"Saito S, Hosokawa G, Tanaka S, Nakamura S. Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent implantation in acute myocardial infarction (PASTA) trial. Catheter Cardiovasc Interv. 1999;48:262\u20138 (PASTA Trial Investigators).","journal-title":"Catheter Cardiovasc Interv"},{"key":"1229_CR115","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1253\/circj.67.369","volume":"67","author":"M Tsuchihashi","year":"2003","unstructured":"Tsuchihashi M, Tsutsui H, Shihara M, Tada H, Kono S, Takeshita A. Comparison of outcomes for patients undergoing balloon angioplasty vs coronary stenting for acute myocardial infarction. Circ J. 2003;67:369\u201374.","journal-title":"Circ J"},{"key":"1229_CR116","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1056\/NEJMoa062598","volume":"355","author":"GJ Laarman","year":"2006","unstructured":"Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006;355:1105\u201313. https:\/\/doi.org\/10.1056\/NEJMoa062598.","journal-title":"N Engl J Med"},{"key":"1229_CR117","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1093\/eurheartj\/ehm402","volume":"28","author":"A Kastrati","year":"2007","unstructured":"Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J. 2007;28:2706\u201313. https:\/\/doi.org\/10.1093\/eurheartj\/ehm402.","journal-title":"Eur Heart J"},{"key":"1229_CR118","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ijcard.2007.12.040","volume":"133","author":"G De Luca","year":"2009","unstructured":"De Luca G, Stone GW, Suryapranata H, Laarman GJ, Menichelli M, Kaiser C, et al. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Int J Cardiol. 2009;133:213\u201322. https:\/\/doi.org\/10.1016\/j.ijcard.2007.12.040.","journal-title":"Int J Cardiol"},{"key":"1229_CR119","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1161\/01.cir.0000103666.25660.77","volume":"108","author":"M Degertekin","year":"2003","unstructured":"Degertekin M, Serruys PW, Tanabe K, Lee CH, Sousa JE, Colombo A, et al. Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis. Circulation. 2003;108:2747\u201350. https:\/\/doi.org\/10.1161\/01.cir.0000103666.25660.77.","journal-title":"Circulation"},{"key":"1229_CR120","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/s0140-6736(04)17275-9","volume":"364","author":"EP McFadden","year":"2004","unstructured":"McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519\u201321. https:\/\/doi.org\/10.1016\/s0140-6736(04)17275-9.","journal-title":"Lancet"},{"key":"1229_CR121","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1161\/circulationaha.107.762047","volume":"118","author":"G Nakazawa","year":"2008","unstructured":"Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008;118:1138\u201345. https:\/\/doi.org\/10.1161\/circulationaha.107.762047.","journal-title":"Circulation"},{"key":"1229_CR122","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jcin.2010.11.003","volume":"4","author":"MA Vink","year":"2011","unstructured":"Vink MA, Dirksen MT, Suttorp MJ, Tijssen JG, van Etten J, Patterson MS, et al. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. JACC Cardiovasc Interv. 2011;4:24\u20139. https:\/\/doi.org\/10.1016\/j.jcin.2010.11.003.","journal-title":"JACC Cardiovasc Interv"},{"key":"1229_CR123","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1161\/circinterventions.114.001360","volume":"7","author":"SG Stone","year":"2014","unstructured":"Stone SG, Serrao GW, Mehran R, Tomey MI, Witzenbichler B, Guagliumi G, et al. Incidence, predictors, and implications of reinfarction after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial. Circ Cardiovasc Interv. 2014;7:543\u201351. https:\/\/doi.org\/10.1161\/circinterventions.114.001360.","journal-title":"Circ Cardiovasc Interv"},{"key":"1229_CR124","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jcin.2009.01.012","volume":"2","author":"N Gonzalo","year":"2009","unstructured":"Gonzalo N, Barlis P, Serruys PW, Garcia-Garcia HM, Onuma Y, Ligthart J, et al. Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable\/unstable angina: insights from optical coherence tomography. JACC Cardiovasc Interv. 2009;2:445\u201352. https:\/\/doi.org\/10.1016\/j.jcin.2009.01.012.","journal-title":"JACC Cardiovasc Interv"},{"key":"1229_CR125","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1161\/circulationaha.107.742312","volume":"117","author":"R Jaffe","year":"2008","unstructured":"Jaffe R, Charron T, Puley G, Dick A, Strauss BH. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation. 2008;117:3152\u20136. https:\/\/doi.org\/10.1161\/circulationaha.107.742312.","journal-title":"Circulation"},{"key":"1229_CR126","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/circinterventions.109.896225","volume":"3","author":"G Ndrepepa","year":"2010","unstructured":"Ndrepepa G, Tiroch K, Keta D, Fusaro M, Seyfarth M, Pache J, et al. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv. 2010;3:27\u201333. https:\/\/doi.org\/10.1161\/circinterventions.109.896225.","journal-title":"Circ Cardiovasc Interv"},{"key":"1229_CR127","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.amjcard.2012.09.015","volume":"111","author":"RW Harrison","year":"2013","unstructured":"Harrison RW, Aggarwal A, Ou FS, Klein LW, Rumsfeld JS, Roe MT, et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol. 2013;111:178\u201384. https:\/\/doi.org\/10.1016\/j.amjcard.2012.09.015.","journal-title":"Am J Cardiol"},{"key":"1229_CR128","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.4244\/eijv8i10a175","volume":"8","author":"H Kelbaek","year":"2013","unstructured":"Kelbaek H, Engstrom T, Ahtarovski KA, Lonborg J, Vejlstrup N, Pedersen F, et al. Deferred stent implantation in patients with ST-segment elevation myocardial infarction: a pilot study. EuroInterv J EuroPCR Collab Working Group Interv Cardiol Eur Soc Cardiol. 2013;8:1126\u201333. https:\/\/doi.org\/10.4244\/eijv8i10a175.","journal-title":"EuroInterv J EuroPCR Collab Working Group Interv Cardiol Eur Soc Cardiol"},{"key":"1229_CR129","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1016\/j.jacc.2014.02.530","volume":"63","author":"D Carrick","year":"2014","unstructured":"Carrick D, Oldroyd KG, McEntegart M, Haig C, Petrie MC, Eteiba H, et al. A randomized trial of deferred stenting versus immediate stenting to prevent no- or slow-reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI). J Am Coll Cardiol. 2014;63:2088\u201398. https:\/\/doi.org\/10.1016\/j.jacc.2014.02.530.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR130","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.116.004101","volume":"9","author":"JS Kim","year":"2016","unstructured":"Kim JS, Lee HJ, Woong Yu C, Kim YM, Hong SJ, Park JH, et al. INNOVATION study (impact of immediate stent implantation versus deferred stent implantation on infarct size and microvascular perfusion in patients with ST-segment-elevation myocardial infarction). Circ Cardiovasc Interv. 2016;9:e004101. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.116.004101.","journal-title":"Circ Cardiovasc Interv"},{"key":"1229_CR131","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.amjcard.2024.05.002","volume":"223","author":"M Nishino","year":"2024","unstructured":"Nishino M, Egami Y, Nakamura H, Abe M, Ohsuga M, Nohara H, et al. Clinical impact of perfusion balloon for ST-segment elevated myocardial infarction: RYUSEI study. Am J Cardiol. 2024;223:43\u201351. https:\/\/doi.org\/10.1016\/j.amjcard.2024.05.002.","journal-title":"Am J Cardiol"},{"key":"1229_CR132","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12928-024-01034-0","volume":"40","author":"M Yoshinaga","year":"2025","unstructured":"Yoshinaga M, Muramatsu T, Ishikawa M, Toriya T, Uwatoko T, Matsuwaki Y, et al. A pilot study of perfusion balloon predilatation in conjunction with intracoronary nicorandil administration for acute coronary syndrome. Cardiovasc Interv Ther. 2025;40:45\u201356. https:\/\/doi.org\/10.1007\/s12928-024-01034-0.","journal-title":"Cardiovasc Interv Ther"},{"key":"1229_CR133","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jacc.2013.05.022","volume":"62","author":"T Palmerini","year":"2013","unstructured":"Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabate M, Valgimigli M, et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2013;62:496\u2013504. https:\/\/doi.org\/10.1016\/j.jacc.2013.05.022.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR134","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ccd.26458","volume":"88","author":"F Philip","year":"2016","unstructured":"Philip F, Stewart S, Southard JA. Very late stent thrombosis with second generation drug eluting stents compared to bare metal stents: network meta-analysis of randomized primary percutaneous coronary intervention trials. Catheter Cardiovasc Interv. 2016;88:38\u201348. https:\/\/doi.org\/10.1002\/ccd.26458.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1229_CR135","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1016\/j.jacc.2019.09.038","volume":"74","author":"P Chichareon","year":"2019","unstructured":"Chichareon P, Modolo R, Collet C, Tenekecioglu E, Vink MA, Oh PC, et al. Efficacy and safety of stents in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2019;74:2572\u201384. https:\/\/doi.org\/10.1016\/j.jacc.2019.09.038.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR136","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.jacc.2020.12.059","volume":"77","author":"S Brugaletta","year":"2021","unstructured":"Brugaletta S, Gomez-Lara J, Ortega-Paz L, Jimenez-Diaz V, Jimenez M, Jim\u00e9nez-Quevedo P, et al. 10-year follow-up of patients with everolimus-eluting versus bare-metal stents after ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2021;77:1165\u201378. https:\/\/doi.org\/10.1016\/j.jacc.2020.12.059.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR137","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/S0140-6736(14)61038-2","volume":"384","author":"T Pilgrim","year":"2014","unstructured":"Pilgrim T, Heg D, Roffi M, Tuller D, Muller O, Vuilliomenet A, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet. 2014;384:2111\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(14)61038-2.","journal-title":"Lancet"},{"key":"1229_CR138","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/s0140-6736(19)31877-x","volume":"394","author":"JF Iglesias","year":"2019","unstructured":"Iglesias JF, Muller O, Heg D, Roffi M, Kurz DJ, Moarof I, et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet. 2019;394:1243\u201353. https:\/\/doi.org\/10.1016\/s0140-6736(19)31877-x.","journal-title":"Lancet"},{"key":"1229_CR139","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(23)02197-9","volume":"402","author":"JF Iglesias","year":"2023","unstructured":"Iglesias JF, Roffi M, Losdat S, Muller O, Degrauwe S, Kurz DJ, et al. Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial. Lancet. 2023;402:1979\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(23)02197-9.","journal-title":"Lancet"},{"key":"1229_CR140","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","volume":"373","author":"P Urban","year":"2015","unstructured":"Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373:2038\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1503943.","journal-title":"N Engl J Med"},{"key":"1229_CR141","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/eurheartj\/ehw203","volume":"38","author":"CK Naber","year":"2017","unstructured":"Naber CK, Urban P, Ong PJ, Valdes-Chavarri M, Abizaid AA, Pocock SJ, et al. Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a leaders free ACS sub-study. Eur Heart J. 2017;38:961\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehw203.","journal-title":"Eur Heart J"},{"key":"1229_CR142","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1161\/CIRCULATIONAHA.119.040241","volume":"141","author":"O Jensen Lisette","year":"2020","unstructured":"Jensen Lisette O, Maeng M, Raungaard B, Kahlert J, Ellert J, Jakobsen L, et al. Randomized comparison of the polymer-free biolimus-coated BioFreedom stent with the ultrathin strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers population treated with percutaneous Coronary intervention: the SORT OUT IX trial. Circulation. 2020;141:2052\u201363. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040241.","journal-title":"Circulation"},{"key":"1229_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102304","volume":"65","author":"S Saito","year":"2023","unstructured":"Saito S, Bennett J, Nef HM, Webster M, Namiki A, Takahashi A, et al. First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with de novo coronary artery lesions: 12-month clinical and imaging data from the multi-centre, international, BIODAPTOR-RCT. EClinMed. 2023;65:102304. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102304.","journal-title":"EClinMed"},{"key":"1229_CR144","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jcin.2025.01.426","volume":"18","author":"S Saito","year":"2025","unstructured":"Saito S, Bennett J, Nef HM, Webster M, Namiki A, Takahashi A, et al. Percutaneous coronary treatment with bioadaptor implant vs drug-eluting stent: 2-year outcomes from BIOADAPTOR RCT. JACC Cardiovasc Interv. 2025;18:988\u201397. https:\/\/doi.org\/10.1016\/j.jcin.2025.01.426.","journal-title":"JACC Cardiovasc Interv"},{"key":"1229_CR145","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(24)02227-X","volume":"404","author":"D Erlinge","year":"2024","unstructured":"Erlinge D, Andersson J, Frobert O, Tornerud M, Hamid M, Kellerth T, et al. Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial. Lancet. 2024;404:1750\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(24)02227-X.","journal-title":"Lancet"},{"key":"1229_CR146","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.ijcard.2012.10.043","volume":"168","author":"T Sawada","year":"2013","unstructured":"Sawada T, Shinke T, Otake H, Mizoguchi T, Iwasaki M, Emoto T, et al. Comparisons of detailed arterial healing response at seven months following implantation of an everolimus- or sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction. Int J Cardiol. 2013;168:960\u20136. https:\/\/doi.org\/10.1016\/j.ijcard.2012.10.043.","journal-title":"Int J Cardiol"},{"key":"1229_CR147","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s12928-023-00921-2","volume":"38","author":"T Muramatsu","year":"2023","unstructured":"Muramatsu T, Kozuma K, Tanabe K, Morino Y, Ako J, Nakamura S, et al. Clinical expert consensus document on drug-coated balloon for coronary artery disease from the Japanese Association of Cardiovascular Intervention and Therapeutics. Cardiovasc Interv Ther. 2023;38:166\u201376. https:\/\/doi.org\/10.1007\/s12928-023-00921-2.","journal-title":"Cardiovasc Interv Ther"},{"key":"1229_CR148","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.jcin.2020.02.043","volume":"13","author":"RV Jeger","year":"2020","unstructured":"Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin ES, et al. Drug-coated balloons for coronary artery disease: third report of the international DCB consensus group. JACC Cardiovasc Interv. 2020;13:1391\u2013402. https:\/\/doi.org\/10.1016\/j.jcin.2020.02.043.","journal-title":"JACC Cardiovasc Interv"},{"key":"1229_CR149","doi-asserted-by":"publisher","first-page":"584","DOI":"10.4244\/EIJV10I5A101","volume":"10","author":"NS Vos","year":"2014","unstructured":"Vos NS, Dirksen MT, Vink MA, van Nooijen FC, Amoroso G, Herrman JP, et al. Safety and feasibility of a PAclitaxel-eluting balloon angioplasty in primary percutaneous coronary intervention in Amsterdam (PAPPA): one-year clinical outcome of a pilot study. EuroIntervention. 2014;10:584\u201390. https:\/\/doi.org\/10.4244\/EIJV10I5A101.","journal-title":"EuroIntervention"},{"key":"1229_CR150","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/j.jcin.2019.04.016","volume":"12","author":"NS Vos","year":"2019","unstructured":"Vos NS, Fagel ND, Amoroso G, Herrman JR, Patterson MS, Piers LH, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction: the REVELATION randomized trial. JACC Cardiovasc Interv. 2019;12:1691\u20139. https:\/\/doi.org\/10.1016\/j.jcin.2019.04.016.","journal-title":"JACC Cardiovasc Interv"},{"key":"1229_CR151","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.4244\/EIJ-D-19-00723","volume":"15","author":"B Scheller","year":"2020","unstructured":"Scheller B, Ohlow MA, Ewen S, Kische S, Rudolph TK, Clever YP, et al. Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial. EuroIntervention. 2020;15:1527\u201333. https:\/\/doi.org\/10.4244\/EIJ-D-19-00723.","journal-title":"EuroIntervention"},{"key":"1229_CR152","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-082945","volume":"388","author":"C Gao","year":"2025","unstructured":"Gao C, Zhu B, Ouyang F, Wen S, Xu Y, Jia W, et al. Stepwise dual antiplatelet therapy de-escalation in patients after drug coated balloon angioplasty (REC-CAGEFREE II): multicentre, randomised, open label, assessor blind, non-inferiority trial. BMJ. 2025;388:e082945. https:\/\/doi.org\/10.1136\/bmj-2024-082945.","journal-title":"BMJ"},{"key":"1229_CR153","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.jacc.2023.09.823","volume":"82","author":"T Kuno","year":"2023","unstructured":"Kuno T, Kiyohara Y, Maehara A, Ueyama HA, Kampaktsis PN, Takagi H, et al. Comparison of intravascular imaging, functional, or angiographically guided coronary intervention. J Am Coll Cardiol. 2023;82:2167\u201376. https:\/\/doi.org\/10.1016\/j.jacc.2023.09.823.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR154","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(23)02454-6","volume":"403","author":"GW Stone","year":"2024","unstructured":"Stone GW, Christiansen EH, Ali ZA, Andreasen LN, Maehara A, Ahmad Y, et al. Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis. Lancet. 2024;403:824\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(23)02454-6.","journal-title":"Lancet"},{"key":"1229_CR155","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1161\/CIRCULATIONAHA.123.067583","volume":"149","author":"D Giacoppo","year":"2024","unstructured":"Giacoppo D, Laudani C, Occhipinti G, Spagnolo M, Greco A, Rochira C, et al. Coronary angiography, intravascular ultrasound, and optical coherence tomography for guiding of percutaneous coronary intervention: a systematic review and network meta-analysis. Circulation. 2024;149:1065\u201386. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067583.","journal-title":"Circulation"},{"key":"1229_CR156","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","volume":"149","author":"M Natsuaki","year":"2024","unstructured":"Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R, et al. An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial. Circulation. 2024;149:585\u2013600. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066720.","journal-title":"Circulation"},{"key":"1229_CR157","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015439","volume":"9","author":"M Nakamura","year":"2020","unstructured":"Nakamura M, Kadota K, Takahashi A, Kanda J, Anzai H, Ishii Y, et al. Relationship between platelet reactivity and ischemic and bleeding events after percutaneous coronary intervention in East Asian patients: 1-year results of the PENDULUM Registry. J Am Heart Assoc. 2020;9:e015439. https:\/\/doi.org\/10.1161\/JAHA.119.015439.","journal-title":"J Am Heart Assoc"},{"key":"1229_CR158","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1001\/jama.2015.15454","volume":"314","author":"SJ Hong","year":"2015","unstructured":"Hong SJ, Kim BK, Shin DH, Nam CM, Kim JS, Ko YG, et al. Effect of intravascular ultrasound-guided vs angiography-guided everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial. JAMA. 2015;314:2155\u201363. https:\/\/doi.org\/10.1001\/jama.2015.15454.","journal-title":"JAMA"},{"key":"1229_CR159","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jcin.2019.09.033","volume":"13","author":"SJ Hong","year":"2020","unstructured":"Hong SJ, Mintz GS, Ahn CM, Kim JS, Kim BK, Ko YG, et al. Effect of intravascular ultrasound-guided drug-eluting stent implantation: 5-year follow-up of the IVUS-XPL randomized trial. JACC Cardiovasc Interv. 2020;13:62\u201371. https:\/\/doi.org\/10.1016\/j.jcin.2019.09.033.","journal-title":"JACC Cardiovasc Interv"},{"key":"1229_CR160","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1016\/j.jacc.2018.09.013","volume":"72","author":"J Zhang","year":"2018","unstructured":"Zhang J, Gao X, Kan J, Ge Z, Han L, Lu S, et al. Intravascular ultrasound versus angiography-guided drug-eluting stent implantation: The ULTIMATE trial. J Am Coll Cardiol. 2018;72:3126\u201337. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.013.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR161","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jcin.2020.10.001","volume":"14","author":"XF Gao","year":"2021","unstructured":"Gao XF, Ge Z, Kong XQ, Kan J, Han L, Lu S, et al. 3-year outcomes of the ULTIMATE trial comparing intravascular ultrasound versus angiography-guided drug-eluting stent implantation. JACC Cardiovasc Interv. 2021;14:247\u201357. https:\/\/doi.org\/10.1016\/j.jcin.2020.10.001.","journal-title":"JACC Cardiovasc Interv"},{"key":"1229_CR162","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/S0140-6736(24)00282-4","volume":"403","author":"X Li","year":"2024","unstructured":"Li X, Ge Z, Kan J, Anjum M, Xie P, Chen X, et al. Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial. Lancet. 2024;403:1855\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(24)00282-4.","journal-title":"Lancet"},{"key":"1229_CR163","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","volume":"403","author":"Z Ge","year":"2024","unstructured":"Ge Z, Kan J, Gao X, Raza A, Zhang JJ, Mohydin BS, et al. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Lancet. 2024;403:1866\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(24)00473-2.","journal-title":"Lancet"},{"key":"1229_CR164","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1001\/jamacardio.2024.0059","volume":"9","author":"PH Lee","year":"2024","unstructured":"Lee PH, Hong SJ, Kim HS, Yoon YW, Lee JY, Oh SJ, et al. Quantitative coronary angiography vs intravascular ultrasonography to guide drug-eluting stent implantation: a randomized clinical trial. JAMA Cardiol. 2024;9:428\u201335. https:\/\/doi.org\/10.1001\/jamacardio.2024.0059.","journal-title":"JAMA Cardiol"},{"key":"1229_CR165","doi-asserted-by":"publisher","first-page":"823","DOI":"10.4244\/EIJV8I7A125","volume":"8","author":"F Prati","year":"2012","unstructured":"Prati F, Di Vito L, Biondi-Zoccai G, Occhipinti M, La Manna A, Tamburino C, et al. Angiography alone versus angiography plus optical coherence tomography to guide decision-making during percutaneous coronary intervention: the Centro per la Lotta contro l\u2019Infarto-Optimisation of Percutaneous Coronary Intervention (CLI-OPCI) study. EuroIntervention. 2012;8:823\u20139. https:\/\/doi.org\/10.4244\/EIJV8I7A125.","journal-title":"EuroIntervention"},{"key":"1229_CR166","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.114.002446","volume":"8","author":"L Antonsen","year":"2015","unstructured":"Antonsen L, Thayssen P, Maehara A, Hansen HS, Junker A, Veien KT, et al. Optical coherence tomography guided percutaneous coronary intervention with Nobori stent implantation in patients with non-ST-segment-elevation myocardial infarction (OCTACS) trial: difference in strut coverage and dynamic malapposition patterns at 6 months. Circ Cardiovasc Interv. 2015;8:e002446. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.114.002446.","journal-title":"Circ Cardiovasc Interv"},{"key":"1229_CR167","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.116.024393","volume":"134","author":"N Meneveau","year":"2016","unstructured":"Meneveau N, Souteyrand G, Motreff P, Caussin C, Amabile N, Ohlmann P, et al. Optical coherence tomography to optimize results of percutaneous coronary intervention in patients with non-ST-elevation acute coronary syndrome: results of the multicenter, randomized DOCTORS study (Does optical coherence tomography optimize results of stenting). Circulation. 2016;134:906\u201317. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.024393.","journal-title":"Circulation"},{"key":"1229_CR168","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ijcard.2017.10.059","volume":"250","author":"P Kala","year":"2018","unstructured":"Kala P, Cervinka P, Jakl M, Kanovsky J, Kupec A, Spacek R, et al. OCT guidance during stent implantation in primary PCI: a randomized multicenter study with nine months of optical coherence tomography follow-up. Int J Cardiol. 2018;250:98\u2013103. https:\/\/doi.org\/10.1016\/j.ijcard.2017.10.059.","journal-title":"Int J Cardiol"},{"key":"1229_CR169","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.jcin.2022.01.298","volume":"15","author":"H Jia","year":"2022","unstructured":"Jia H, Dai J, He L, Xu Y, Shi Y, Zhao L, et al. EROSION III: A multicenter RCT of OCT-guided reperfusion in STEMI with early infarct artery patency. JACC Cardiovasc Interv. 2022;15:846\u201356. https:\/\/doi.org\/10.1016\/j.jcin.2022.01.298.","journal-title":"JACC Cardiovasc Interv"},{"key":"1229_CR170","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1056\/NEJMoa2305861","volume":"389","author":"ZA Ali","year":"2023","unstructured":"Ali ZA, Landmesser U, Maehara A, Matsumura M, Shlofmitz RA, Guagliumi G, et al. Optical coherence tomography-guided versus angiography-guided PCI. N Engl J Med. 2023;389:1466\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2305861.","journal-title":"N Engl J Med"},{"key":"1229_CR171","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa2307770","volume":"389","author":"NR Holm","year":"2023","unstructured":"Holm NR, Andreasen LN, Neghabat O, Laanmets P, Kumsars I, Bennett J, et al. OCT or angiography guidance for PCI in complex bifurcation lesions. N Engl J Med. 2023;389:1477\u201387. https:\/\/doi.org\/10.1056\/NEJMoa2307770.","journal-title":"N Engl J Med"},{"key":"1229_CR172","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S0140-6736(24)01454-5","volume":"404","author":"SJ Hong","year":"2024","unstructured":"Hong SJ, Lee SJ, Lee SH, Lee JY, Cho DK, Kim JW, et al. Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea. Lancet. 2024;404:1029\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(24)01454-5.","journal-title":"Lancet"},{"key":"1229_CR173","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1056\/NEJMoa2216607","volume":"388","author":"JM Lee","year":"2023","unstructured":"Lee JM, Choi KH, Song YB, Lee JY, Lee SJ, Lee SY, et al. Intravascular imaging-guided or angiography-guided complex PCI. N Engl J Med. 2023;388:1668\u201379. https:\/\/doi.org\/10.1056\/NEJMoa2216607.","journal-title":"N Engl J Med"},{"key":"1229_CR174","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1161\/CIRCULATIONAHA.123.066429","volume":"148","author":"DY Kang","year":"2023","unstructured":"Kang DY, Ahn JM, Yun SC, Hur SH, Cho YK, Lee CH, et al. Optical coherence tomography-guided or intravascular ultrasound-guided percutaneous coronary intervention: the OCTIVUS randomized clinical trial. Circulation. 2023;148:1195\u2013206. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066429.","journal-title":"Circulation"},{"key":"1229_CR175","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1016\/S0140-6736(16)31922-5","volume":"388","author":"ZA Ali","year":"2016","unstructured":"Ali ZA, Maehara A, Genereux P, Shlofmitz RA, Fabbiocchi F, Nazif TM, et al. Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial. Lancet. 2016;388:2618\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(16)31922-5.","journal-title":"Lancet"},{"key":"1229_CR176","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.120.009452","volume":"14","author":"D Chamie","year":"2021","unstructured":"Chamie D, Costa JR Jr., Damiani LP, Siqueira D, Braga S, Costa R, et al. Optical coherence tomography versus intravascular ultrasound and angiography to guide percutaneous coronary interventions: the iSIGHT randomized trial. Circ Cardiovasc Interv. 2021;14:e009452. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.120.009452.","journal-title":"Circ Cardiovasc Interv"},{"key":"1229_CR177","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1161\/01.CIR.92.6.1408","volume":"92","author":"PJ de Feyter","year":"1995","unstructured":"de Feyter PJ, Ozaki Y, Baptista J, Escaned J, Di Mario C, de Jaegere PP, et al. Ischemia-related lesion characteristics in patients with stable or unstable angina. A study with intracoronary angioscopy and ultrasound. Circulation. 1995;92:1408\u201313.","journal-title":"Circulation"},{"key":"1229_CR178","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jcmg.2012.12.007","volume":"6","author":"F Prati","year":"2013","unstructured":"Prati F, Uemura S, Souteyrand G, Virmani R, Motreff P, Di Vito L, et al. OCT-based diagnosis and management of STEMI associated with intact fibrous cap. JACC Cardiovasc Imaging. 2013;6:283\u20137. https:\/\/doi.org\/10.1016\/j.jcmg.2012.12.007.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1229_CR179","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/eurheartj\/ehw381","volume":"38","author":"H Jia","year":"2017","unstructured":"Jia H, Dai J, Hou J, Xing L, Ma L, Liu H, et al. Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion (the EROSION study). Eur Heart J. 2017;38:792\u2013800. https:\/\/doi.org\/10.1093\/eurheartj\/ehw381.","journal-title":"Eur Heart J"},{"key":"1229_CR180","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/eurheartj\/ehz520","volume":"41","author":"F Prati","year":"2020","unstructured":"Prati F, Romagnoli E, Gatto L, La Manna A, Burzotta F, Ozaki Y, et al. Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study. Eur Heart J. 2020;41:383\u201391. https:\/\/doi.org\/10.1093\/eurheartj\/ehz520.","journal-title":"Eur Heart J"},{"key":"1229_CR181","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jcin.2013.04.012","volume":"6","author":"RD Madder","year":"2013","unstructured":"Madder RD, Goldstein JA, Madden SP, Puri R, Wolski K, Hendricks M, et al. Detection by near-infrared spectroscopy of large lipid core plaques at culprit sites in patients with acute ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2013;6:838\u201346.","journal-title":"JACC Cardiovasc Interv"},{"key":"1229_CR182","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1161\/ATVBAHA.115.306849","volume":"36","author":"RD Madder","year":"2016","unstructured":"Madder RD, Puri R, Muller JE, Harnek J, Gotberg M, VanOosterhout S, et al. Confirmation of the intracoronary near-infrared spectroscopy threshold of lipid-rich plaques that underlie ST-segment-elevation myocardial infarction. Arterioscler Thromb Vasc Biol. 2016;36:1010\u20135.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1229_CR183","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.25754","author":"RD Madder","year":"2014","unstructured":"Madder RD, Husaini M, Davis AT, Van Oosterhout S, Harnek J, Gotberg M, et al. Detection by near-infrared spectroscopy of large lipid cores at culprit sites in patients with non-st-segment elevation myocardial infarction and unstable angina. Catheter Cardiovasc Interv. 2014. https:\/\/doi.org\/10.1002\/ccd.25754.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1229_CR184","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jcin.2015.03.016","volume":"8","author":"AS Kini","year":"2015","unstructured":"Kini AS, Motoyama S, Vengrenyuk Y, Feig JE, Pena J, Baber U, et al. Multimodality intravascular imaging to predict periprocedural myocardial infarction during percutaneous coronary intervention. JACC Cardiovasc Interv. 2015;8:937\u201345. https:\/\/doi.org\/10.1016\/j.jcin.2015.03.016.","journal-title":"JACC Cardiovasc Interv"},{"key":"1229_CR185","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1253\/circj.CJ-14-0758","volume":"79","author":"Y Ozaki","year":"2015","unstructured":"Ozaki Y, Ohota M, Ismail TF, Okumura M, Ishikawa M, Muramatsu T. Thin cap fibroatheroma defined as lipid core abutting lumen (LCAL) on integrated backscatter intravascular ultrasound - comparison with optical coherence tomography and correlation with peri-procedural myocardial infarction. Circ J. 2015;79:808\u201317. https:\/\/doi.org\/10.1253\/circj.CJ-14-0758.","journal-title":"Circ J"},{"key":"1229_CR186","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1093\/eurheartj\/ehy285","volume":"39","author":"L Raber","year":"2018","unstructured":"Raber L, Mintz GS, Koskinas KC, Johnson TW, Holm NR, Onuma Y, et al. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur Heart J. 2018;39:3281\u2013300. https:\/\/doi.org\/10.1093\/eurheartj\/ehy285.","journal-title":"Eur Heart J"},{"key":"1229_CR187","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jcmg.2015.08.013","volume":"8","author":"F Prati","year":"2015","unstructured":"Prati F, Romagnoli E, Burzotta F, Limbruno U, Gatto L, La Manna A, et al. Clinical impact of OCT findings during PCI: the CLI-OPCI II study. JACC Cardiovasc Imaging. 2015;8:1297\u2013305. https:\/\/doi.org\/10.1016\/j.jcmg.2015.08.013.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1229_CR188","doi-asserted-by":"publisher","DOI":"10.1161\/circinterventions.115.003726","author":"F Prati","year":"2016","unstructured":"Prati F, Romagnoli E, Gatto L, La Manna A, Burzotta F, Limbruno U, et al. Clinical impact of suboptimal stenting and residual intrastent plaque\/thrombus protrusion in patients with acute coronary syndrome: the CLI-OPCI ACS substudy (Centro per la Lotta Contro L\u2019Infarto-Optimization of Percutaneous Coronary Intervention in Acute Coronary Syndrome). Circ Cardiovasc Interv. 2016. https:\/\/doi.org\/10.1161\/circinterventions.115.003726.","journal-title":"Circ Cardiovasc Interv"},{"key":"1229_CR189","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1093\/eurheartj\/ehx351","volume":"38","author":"T Kubo","year":"2017","unstructured":"Kubo T, Shinke T, Okamura T, Hibi K, Nakazawa G, Morino Y, et al. Optical frequency domain imaging vs. intravascular ultrasound in percutaneous coronary intervention (OPINION trial): one-year angiographic and clinical results. Eur Heart J. 2017;38:3139\u201347. https:\/\/doi.org\/10.1093\/eurheartj\/ehx351.","journal-title":"Eur Heart J"},{"key":"1229_CR190","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.4244\/eijv9i9a183","volume":"9","author":"MD Radu","year":"2014","unstructured":"Radu MD, Raber L, Heo J, Gogas BD, Jorgensen E, Kelbaek H, et al. Natural history of optical coherence tomography-detected non-flow-limiting edge dissections following drug-eluting stent implantation. EuroInterv J EuroPCR Collaboration Working Group Interv Cardiol Eur Soc Cardiol. 2014;9:1085\u201394. https:\/\/doi.org\/10.4244\/eijv9i9a183.","journal-title":"EuroInterv J EuroPCR Collaboration Working Group Interv Cardiol Eur Soc Cardiol"},{"key":"1229_CR191","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/ehjci\/jeu003","volume":"15","author":"D De Cock","year":"2014","unstructured":"De Cock D, Bennett J, Ughi GJ, Dubois C, Sinnaeve P, Dhooge J, et al. Healing course of acute vessel wall injury after drug-eluting stent implantation assessed by optical coherence tomography. Eur Heart J Cardiovasc Imaging. 2014;15:800\u20139. https:\/\/doi.org\/10.1093\/ehjci\/jeu003.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1229_CR192","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/ccd.25855","volume":"86","author":"KP Bouki","year":"2015","unstructured":"Bouki KP, Sakkali E, Toutouzas K, Vlad D, Barmperis D, Phychari S, et al. Impact of coronary artery stent edge dissections on long-term clinical outcome in patients with acute coronary syndrome: an optical coherence tomography study. Catheter Cardiovasc Interv. 2015;86:237\u201346. https:\/\/doi.org\/10.1002\/ccd.25855.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1229_CR193","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jcin.2013.03.019","volume":"6","author":"D Chamie","year":"2013","unstructured":"Chamie D, Bezerra HG, Attizzani GF, Yamamoto H, Kanaya T, Stefano GT, et al. Incidence, predictors, morphological characteristics, and clinical outcomes of stent edge dissections detected by optical coherence tomography. JACC Cardiovasc Interv. 2013;6:800\u201313. https:\/\/doi.org\/10.1016\/j.jcin.2013.03.019.","journal-title":"JACC Cardiovasc Interv"},{"key":"1229_CR194","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/ehjci\/jes299","volume":"14","author":"H Kawamori","year":"2013","unstructured":"Kawamori H, Shite J, Shinke T, Otake H, Matsumoto D, Nakagawa M, et al. Natural consequence of post-intervention stent malapposition, thrombus, tissue prolapse, and dissection assessed by optical coherence tomography at mid-term follow-up. Eur Heart J Cardiovasc Imaging. 2013;14:865\u201375. https:\/\/doi.org\/10.1093\/ehjci\/jes299.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1229_CR195","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1161\/circulationaha.115.019071","volume":"133","author":"M Taniwaki","year":"2016","unstructured":"Taniwaki M, Radu MD, Zaugg S, Amabile N, Garcia-Garcia HM, Yamaji K, et al. Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography. Circulation. 2016;133:650\u201360. https:\/\/doi.org\/10.1161\/circulationaha.115.019071.","journal-title":"Circulation"},{"key":"1229_CR196","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jcin.2010.03.007","volume":"3","author":"DH Steinberg","year":"2010","unstructured":"Steinberg DH, Mintz GS, Mandinov L, Yu A, Ellis SG, Grube E, et al. Long-term impact of routinely detected early and late incomplete stent apposition: an integrated intravascular ultrasound analysis of the TAXUS IV, V, and VI and TAXUS ATLAS workhorse, long lesion, and direct stent studies. JACC Cardiovasc Interv. 2010;3:486\u201394. https:\/\/doi.org\/10.1016\/j.jcin.2010.03.007.","journal-title":"JACC Cardiovasc Interv"},{"key":"1229_CR197","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1161\/circulationaha.109.906040","volume":"122","author":"N Guo","year":"2010","unstructured":"Guo N, Maehara A, Mintz GS, He Y, Xu K, Wu X, et al. Incidence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction: an intravascular ultrasound substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Circulation. 2010;122:1077\u201384. https:\/\/doi.org\/10.1161\/circulationaha.109.906040.","journal-title":"Circulation"},{"key":"1229_CR198","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.26974","author":"E Romagnoli","year":"2017","unstructured":"Romagnoli E, Gatto L, La Manna A, Burzotta F, Taglieri N, Saia F, et al. Role of residual acute stent malapposition in percutaneous coronary interventions. Catheter Cardiovasc Interv. 2017. https:\/\/doi.org\/10.1002\/ccd.26974.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1229_CR199","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1093\/eurheartj\/ehq066","volume":"31","author":"Y Ozaki","year":"2010","unstructured":"Ozaki Y, Okumura M, Ismail TF, Naruse H, Hattori K, Kan S, et al. The fate of incomplete stent apposition with drug-eluting stents: an optical coherence tomography-based natural history study. Eur Heart J. 2010;31:1470\u20136. https:\/\/doi.org\/10.1093\/eurheartj\/ehq066.","journal-title":"Eur Heart J"},{"key":"1229_CR200","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jacasi.2024.04.001","volume":"4","author":"H Kim","year":"2024","unstructured":"Kim H, Ahn J-M, Kang D-Y, Lee J, Choi Y, Park S-J, et al. Management of coronary vulnerable plaque with medical therapy or local preventive percutaneous coronary intervention. JACC: ASIA. 2024;4:425\u201343. https:\/\/doi.org\/10.1016\/j.jacasi.2024.04.001.","journal-title":"JACC: ASIA"},{"key":"1229_CR201","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1093\/eurheartj\/ehaa227","volume":"41","author":"M Tomaniak","year":"2020","unstructured":"Tomaniak M, Katagiri Y, Modolo R, de Silva R, Khamis RY, Bourantas CV, et al. Vulnerable plaques and patients: state-of-the-art. Eur Heart J. 2020;41:2997\u20133004. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa227.","journal-title":"Eur Heart J"},{"key":"1229_CR202","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1093\/eurheartj\/ehab433","volume":"42","author":"E Kedhi","year":"2021","unstructured":"Kedhi E, Berta B, Roleder T, Hermanides RS, et al. Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial. Eur Heart J. 2021;42:4671\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehab433.","journal-title":"Eur Heart J"},{"key":"1229_CR203","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1001\/jamacardio.2023.2910","volume":"8","author":"JQ Mol","year":"2023","unstructured":"Mol JQ, Volleberg R, Belkacemi A, Hermanides RS, Meuwissen M, Protopopov AV, et al. Fractional flow reserve-negative high-risk plaques and clinical outcomes after myocardial infarction. JAMA Cardiol. 2023;8:1013\u201321. https:\/\/doi.org\/10.1001\/jamacardio.2023.2910.","journal-title":"JAMA Cardiol"},{"key":"1229_CR204","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/S0140-6736(24)00413-6","volume":"403","author":"SJ Park","year":"2024","unstructured":"Park SJ, Ahn JM, Kang DY, Yun SC, Ahn YK, Kim WJ, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet. 2024;403:1753\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(24)00413-6.","journal-title":"Lancet"},{"key":"1229_CR205","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132895","volume":"421","author":"R Ozaki","year":"2025","unstructured":"Ozaki R, Motoyama S, Ozaki Y, Sarai M, Kawai H, Ismail TF, et al. Impact of CT-angiography derived plaque characteristics on cardiac events in patients with a negative invasive fractional flow reserve. Int J Cardiol. 2025;421:132895. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132895.","journal-title":"Int J Cardiol"},{"key":"1229_CR206","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.85768","volume":"1","author":"D Carrick","year":"2016","unstructured":"Carrick D, Haig C, Carberry J, May VTY, McCartney P, Welsh P, et al. Microvascular resistance of the culprit coronary artery in acute ST-elevation myocardial infarction. JCI Insight. 2016;1:e85768. https:\/\/doi.org\/10.1172\/jci.insight.85768.","journal-title":"JCI Insight"},{"key":"1229_CR207","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/ccd.27529","volume":"92","author":"T Murai","year":"2018","unstructured":"Murai T, Yonetsu T, Kanaji Y, Usui E, Hoshino M, Hada M, et al. Prognostic value of the index of microcirculatory resistance after percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome. Catheter Cardiovasc Interv. 2018;92:1063\u201374. https:\/\/doi.org\/10.1002\/ccd.27529.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1229_CR208","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/MCC.0000000000001283","volume":"31","author":"L Baldetti","year":"2025","unstructured":"Baldetti L, Cianfanelli L, Scandroglio AM. The intra-aortic balloon pump: a modern practical perspective. Curr Opin Crit Care. 2025;31:451\u201363. https:\/\/doi.org\/10.1097\/MCC.0000000000001283.","journal-title":"Curr Opin Crit Care"},{"key":"1229_CR209","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1208410","volume":"367","author":"H Thiele","year":"2012","unstructured":"Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367:1287\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1208410.","journal-title":"N Engl J Med"},{"key":"1229_CR210","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/s0140-6736(13)61783-3","volume":"382","author":"H Thiele","year":"2013","unstructured":"Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet. 2013;382:1638\u201345. https:\/\/doi.org\/10.1016\/s0140-6736(13)61783-3.","journal-title":"Lancet"},{"key":"1229_CR211","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jama.2011.1280","volume":"306","author":"MR Patel","year":"2011","unstructured":"Patel MR, Smalling RW, Thiele H, Barnhart HX, Zhou Y, Chandra P, et al. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. JAMA. 2011;306:1329\u201337. https:\/\/doi.org\/10.1001\/jama.2011.1280.","journal-title":"JAMA"},{"key":"1229_CR212","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1253\/circj.CJ-19-0133","volume":"83","author":"K Kimura","year":"2019","unstructured":"Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, et al. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circ J. 2019;83:1085\u2013196. https:\/\/doi.org\/10.1253\/circj.CJ-19-0133.","journal-title":"Circ J"},{"key":"1229_CR213","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13092198","author":"K Farhat","year":"2025","unstructured":"Farhat K, Pollanen S, Damrongwatanasuk R, DiChiacchio L, Salerno C, Sikand N, et al. The role of Impella in cardiogenic shock in the post-DanGer shock era. Biomedicines. 2025. https:\/\/doi.org\/10.3390\/biomedicines13092198.","journal-title":"Biomedicines"},{"key":"1229_CR214","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.amjcard.2023.06.082","volume":"203","author":"Y Nishimoto","year":"2023","unstructured":"Nishimoto Y, Ohbe H, Matsui H, Nakata J, Takiguchi T, Nakajima M, et al. Trends in mechanical circulatory support use and outcomes of patients with cardiogenic shock in Japan, 2010 to 2020 (from a Nationwide Inpatient Database Study). Am J Cardiol. 2023;203:203\u201311. https:\/\/doi.org\/10.1016\/j.amjcard.2023.06.082.","journal-title":"Am J Cardiol"},{"key":"1229_CR215","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.031838","volume":"12","author":"Y Nishimoto","year":"2023","unstructured":"Nishimoto Y, Inohara T, Kohsaka S, Sakakura K, Kawai T, Kikuchi A, et al. Changing trends in mechanical circulatory support use and outcomes in patients undergoing percutaneous coronary interventions for acute coronary syndrome complicated with cardiogenic shock: insights from a nationwide registry in Japan. J Am Heart Assoc. 2023;12:e031838. https:\/\/doi.org\/10.1161\/JAHA.123.031838.","journal-title":"J Am Heart Assoc"},{"key":"1229_CR216","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/j.jacc.2008.05.065","volume":"52","author":"M Seyfarth","year":"2008","unstructured":"Seyfarth M, Sibbing D, Bauer I, Frohlich G, Bott-Flugel L, Byrne R, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52:1584\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2008.05.065.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR217","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.031401","volume":"12","author":"MB Basir","year":"2023","unstructured":"Basir MB, Lemor A, Gorgis S, Patel KC, Kolski BC, Bharadwaj AS, et al. Early utilization of mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock: the National Cardiogenic Shock Initiative. J Am Heart Assoc. 2023;12:e031401. https:\/\/doi.org\/10.1161\/JAHA.123.031401.","journal-title":"J Am Heart Assoc"},{"key":"1229_CR218","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jacc.2016.10.022","volume":"69","author":"DM Ouweneel","year":"2017","unstructured":"Ouweneel DM, Eriksen E, Sjauw KD, van Dongen IM, Hirsch A, Packer EJ, et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2017;69:278\u201387. https:\/\/doi.org\/10.1016\/j.jacc.2016.10.022.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR219","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1161\/CIRCULATIONAHA.118.036614","volume":"139","author":"B Schrage","year":"2019","unstructured":"Schrage B, Ibrahim K, Loehn T, Werner N, Sinning JM, Pappalardo F, et al. Impella support for acute myocardial infarction complicated by cardiogenic shock. Circulation. 2019;139:1249\u201358. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.036614.","journal-title":"Circulation"},{"key":"1229_CR220","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1056\/NEJMc2508284","volume":"393","author":"JE Moller","year":"2025","unstructured":"Moller JE, Beske RP, Engstrom T, Jensen LO, Eiskjaer H, Mangner N, et al. Long-term outcomes of the DanGer shock trial. N Engl J Med. 2025;393:1037\u20138. https:\/\/doi.org\/10.1056\/NEJMc2508284.","journal-title":"N Engl J Med"},{"key":"1229_CR221","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ahj.2022.08.011","volume":"254","author":"NK Kapur","year":"2022","unstructured":"Kapur NK, Kim RJ, Moses JW, Stone GW, Udelson JE, Ben-Yehuda O, et al. Primary left ventricular unloading with delayed reperfusion in patients with anterior ST-elevation myocardial infarction: rationale and design of the STEMI-DTU randomized pivotal trial. Am Heart J. 2022;254:122\u201332. https:\/\/doi.org\/10.1016\/j.ahj.2022.08.011.","journal-title":"Am Heart J"},{"key":"1229_CR222","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ahj.2023.08.066","volume":"265","author":"C Delmas","year":"2023","unstructured":"Delmas C, Laine M, Schurtz G, Roubille F, Coste P, Leurent G, et al. Rationale and design of the ULYSS trial: a randomized multicenter evaluation of the efficacy of early Impella CP implantation in acute coronary syndrome complicated by cardiogenic shock. Am Heart J. 2023;265:203\u201312. https:\/\/doi.org\/10.1016\/j.ahj.2023.08.066.","journal-title":"Am Heart J"},{"key":"1229_CR223","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJMoa2307227","volume":"389","author":"H Thiele","year":"2023","unstructured":"Thiele H, Zeymer U, Akin I, Behnes M, Rassaf T, Mahabadi AA, et al. Extracorporeal life support in infarct-related cardiogenic shock. N Engl J Med. 2023;389:1286\u201397. https:\/\/doi.org\/10.1056\/NEJMoa2307227.","journal-title":"N Engl J Med"},{"key":"1229_CR224","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1093\/eurheartj\/ehae610","volume":"45","author":"S Desch","year":"2024","unstructured":"Desch S, Zeymer U, Akin I, Behnes M, Duerschmied D, Rassaf T, et al. Routine extracorporeal life support in infarct-related cardiogenic shock: 1-year results of the ECLS-SHOCK trial. Eur Heart J. 2024;45:4200\u20133. https:\/\/doi.org\/10.1093\/eurheartj\/ehae610.","journal-title":"Eur Heart J"},{"key":"1229_CR225","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1097\/ccm.0000000000001828","volume":"44","author":"S Aso","year":"2016","unstructured":"Aso S, Matsui H, Fushimi K, Yasunaga H. The effect of intraaortic balloon pumping under venoarterial extracorporeal membrane oxygenation on mortality of cardiogenic patients: an analysis using a nationwide inpatient database. Crit Care Med. 2016;44:1974\u20139. https:\/\/doi.org\/10.1097\/ccm.0000000000001828.","journal-title":"Crit Care Med"},{"key":"1229_CR226","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030819","volume":"12","author":"Y Saito","year":"2023","unstructured":"Saito Y, Tateishi K, Toda K, Matsumiya G, Kobayashi Y. Complications and outcomes of Impella treatment in cardiogenic shock patients with and without acute myocardial infarction. J Am Heart Assoc. 2023;12:e030819. https:\/\/doi.org\/10.1161\/JAHA.123.030819.","journal-title":"J Am Heart Assoc"},{"key":"1229_CR227","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/eurheartj\/ehp292","volume":"30","author":"JM Cheng","year":"2009","unstructured":"Cheng JM, den Uil CA, Hoeks SE, van der Ent M, Jewbali LS, van Domburg RT, et al. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J. 2009;30:2102\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehp292.","journal-title":"Eur Heart J"},{"key":"1229_CR228","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/j.jacc.2010.10.062","volume":"57","author":"RC Starling","year":"2011","unstructured":"Starling RC, Naka Y, Boyle AJ, Gonzalez-Stawinski G, John R, Jorde U, et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am College Cardiol. 2011;57:1890\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2010.10.062.","journal-title":"J Am College Cardiol"},{"key":"1229_CR229","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1097\/CCM.0b013e3181e8acf7","volume":"38","author":"JJ Sheu","year":"2010","unstructured":"Sheu JJ, Tsai TH, Lee FY, Fang HY, Sun CK, Leu S, et al. Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit Care Med. 2010;38:1810\u20137. https:\/\/doi.org\/10.1097\/CCM.0b013e3181e8acf7.","journal-title":"Crit Care Med"},{"key":"1229_CR230","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jcin.2016.02.046","volume":"9","author":"TM Atkinson","year":"2016","unstructured":"Atkinson TM, Ohman EM, O\u2019Neill WW, Rab T, Cigarroa JE. A practical approach to mechanical circulatory support in patients undergoing percutaneous coronary intervention: an interventional perspective. JACC Cardiovasc Interv. 2016;9:871\u201383. https:\/\/doi.org\/10.1016\/j.jcin.2016.02.046.","journal-title":"JACC Cardiovasc Interv"},{"key":"1229_CR231","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.4244\/eijv7i12a226","volume":"7","author":"RJ Cubeddu","year":"2012","unstructured":"Cubeddu RJ, Lago R, Horvath SA, Vignola PA, O\u2019Neill W, Palacios IF. Use of the Impella 2.5 system alone, after and in combination with an intra-aortic balloon pump in patients with cardiogenic shock: case description and review of the literature. EuroInterv J EuroPCR Collab Working Group Interv Cardiol Eur Soc Cardiol. 2012;7:1453\u201360. https:\/\/doi.org\/10.4244\/eijv7i12a226.","journal-title":"EuroInterv J EuroPCR Collab Working Group Interv Cardiol Eur Soc Cardiol"},{"key":"1229_CR232","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/MAT.0b013e3181f7478e","volume":"56","author":"DM Wiktor","year":"2010","unstructured":"Wiktor DM, Sawlani N, Kanthi Y, Sipahi I, Fang JC, Blitz A. Successful combined use of Impella Recover 2.5 device and intra-aortic balloon pump support in cardiogenic shock from acute myocardial infarction. ASAIO J. 2010;56:519\u201321. https:\/\/doi.org\/10.1097\/MAT.0b013e3181f7478e.","journal-title":"ASAIO J"},{"key":"1229_CR233","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ijcard.2015.07.065","volume":"201","author":"F Burzotta","year":"2015","unstructured":"Burzotta F, Trani C, Doshi SN, Townend J, van Geuns RJ, Hunziker P, et al. Impella ventricular support in clinical practice: collaborative viewpoint from a European expert user group. Int J Cardiol. 2015;201:684\u201391. https:\/\/doi.org\/10.1016\/j.ijcard.2015.07.065.","journal-title":"Int J Cardiol"},{"key":"1229_CR234","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/s0140-6736(17)30397-5","volume":"389","author":"F Costa","year":"2017","unstructured":"Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389:1025\u201334. https:\/\/doi.org\/10.1016\/s0140-6736(17)30397-5.","journal-title":"Lancet"},{"key":"1229_CR235","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx419","author":"M Valgimigli","year":"2017","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017. https:\/\/doi.org\/10.1093\/eurheartj\/ehx419.","journal-title":"Eur Heart J"},{"key":"1229_CR236","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1161\/circulationaha.117.028924","volume":"137","author":"Y Yoshikawa","year":"2018","unstructured":"Yoshikawa Y, Shiomi H, Watanabe H, Natsuaki M, Kondo H, Tamura T, et al. Validating utility of dual antiplatelet therapy score in a large pooled cohort from 3 Japanese percutaneous coronary intervention studies. Circulation. 2018;137:551\u201362. https:\/\/doi.org\/10.1161\/circulationaha.117.028924.","journal-title":"Circulation"},{"key":"1229_CR237","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","volume":"40","author":"P Urban","year":"2019","unstructured":"Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019;40:2632\u201353. https:\/\/doi.org\/10.1093\/eurheartj\/ehz372.","journal-title":"Eur Heart J"},{"key":"1229_CR238","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.008307","volume":"12","author":"M Natsuaki","year":"2019","unstructured":"Natsuaki M, Morimoto T, Shiomi H, Yamaji K, Watanabe H, Shizuta S, et al. Application of the academic research consortium high bleeding risk criteria in an all-comers registry of percutaneous coronary intervention. Circ Cardiovasc Interv. 2019;12:e008307. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.119.008307.","journal-title":"Circ Cardiovasc Interv"},{"key":"1229_CR239","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1253\/circj.CJ-19-1109","volume":"84","author":"M Nakamura","year":"2020","unstructured":"Nakamura M, Kimura K, Kimura T, Ishihara M, Otsuka F, Kozuma K, et al. JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease. Circ J. 2020;84:831\u201365. https:\/\/doi.org\/10.1253\/circj.CJ-19-1109.","journal-title":"Circ J"},{"key":"1229_CR240","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1253\/circj.CJ-20-0836","volume":"85","author":"M Natsuaki","year":"2021","unstructured":"Natsuaki M, Morimoto T, Shiomi H, Ehara N, Taniguchi R, Tamura T, et al. Application of the modified high bleeding risk criteria for Japanese patients in an all-comers registry of percutaneous coronary intervention - from the CREDO-Kyoto registry cohort-3. Circ J. 2021;85:769\u201381. https:\/\/doi.org\/10.1253\/circj.CJ-20-0836.","journal-title":"Circ J"},{"key":"1229_CR241","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"P Vranckx","year":"2018","unstructured":"Vranckx P, Valgimigli M, Juni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392:940\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(18)31858-0.","journal-title":"Lancet"},{"key":"1229_CR242","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2019.3355","author":"M Tomaniak","year":"2019","unstructured":"Tomaniak M, Chichareon P, Onuma Y, Deliargyris EN, Takahashi K, Kogame N, et al. Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes: a post hoc analysis of the randomized GLOBAL LEADERS trial. JAMA Cardiol. 2019. https:\/\/doi.org\/10.1001\/jamacardio.2019.3355.","journal-title":"JAMA Cardiol"},{"key":"1229_CR243","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","volume":"149","author":"SJ Hong","year":"2024","unstructured":"Hong SJ, Lee SJ, Suh Y, Yun KH, Kang TS, Shin S, et al. Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial. Circulation. 2024;149:562\u201373. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066943.","journal-title":"Circulation"},{"key":"1229_CR244","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1001\/jama.2019.8146","volume":"321","author":"JY Hahn","year":"2019","unstructured":"Hahn JY, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019;321:2428\u201337. https:\/\/doi.org\/10.1001\/jama.2019.8146.","journal-title":"JAMA"},{"key":"1229_CR245","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","volume":"381","author":"R Mehran","year":"2019","unstructured":"Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381:2032\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1908419.","journal-title":"N Engl J Med"},{"key":"1229_CR246","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1093\/eurheartj\/ehaa670","volume":"41","author":"U Baber","year":"2020","unstructured":"Baber U, Dangas G, Angiolillo DJ, Cohen DJ, Sharma SK, Nicolas J, et al. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J. 2020;41:3533\u201345. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa670.","journal-title":"Eur Heart J"},{"key":"1229_CR247","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1001\/jama.2020.7580","volume":"323","author":"BK Kim","year":"2020","unstructured":"Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020;323:2407\u201316. https:\/\/doi.org\/10.1001\/jama.2020.7580.","journal-title":"JAMA"},{"key":"1229_CR248","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jcin.2020.11.036","volume":"14","author":"SJ Lee","year":"2021","unstructured":"Lee SJ, Cho JY, Kim BK, Yun KH, Suh Y, Cho YH, et al. Ticagrelor monotherapy versus ticagrelor with aspirin in patients with\u00a0ST-segment elevation myocardial\u00a0infarction. JACC Cardiovasc Interv. 2021;14:431\u201340. https:\/\/doi.org\/10.1016\/j.jcin.2020.11.036.","journal-title":"JACC Cardiovasc Interv"},{"key":"1229_CR249","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108749","author":"M Valgimigli","year":"2021","unstructured":"Valgimigli M, Frigoli E, Heg D, Tijssen J, Juni P, Vranckx P, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2108749.","journal-title":"N Engl J Med"},{"key":"1229_CR250","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.121.056680","author":"PC Smits","year":"2021","unstructured":"Smits PC, Frigoli E, Tijssen J, J\u00fcni P, Vranckx P, Ozaki Y, et al. Abbreviated antiplatelet therapy in patients at high bleeding risk with or without oral anticoagulant therapy after coronary stenting: an open-label, randomized, controlled trial. Circulation. 2021. https:\/\/doi.org\/10.1161\/circulationaha.121.056680.","journal-title":"Circulation"},{"key":"1229_CR251","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/ajg.2010.436","volume":"106","author":"B Cryer","year":"2011","unstructured":"Cryer B, Bhatt DL, Lanza FL, Dong JF, Lichtenberger LM, Marathi UK. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol. 2011;106:272\u20137. https:\/\/doi.org\/10.1038\/ajg.2010.436.","journal-title":"Am J Gastroenterol"},{"key":"1229_CR252","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s00380-019-01484-0","volume":"35","author":"S Uchiyama","year":"2020","unstructured":"Uchiyama S, Goto S, Origasa H, Uemura N, Sugano K, Hiraishi H, et al. Major cardiovascular and bleeding events with long-term use of aspirin in patients with prior cardiovascular diseases: 1-year follow-up results from the Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study. Heart Vessels. 2020;35:170\u20136. https:\/\/doi.org\/10.1007\/s00380-019-01484-0.","journal-title":"Heart Vessels"},{"key":"1229_CR253","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s00535-013-0839-5","volume":"49","author":"N Uemura","year":"2014","unstructured":"Uemura N, Sugano K, Hiraishi H, Shimada K, Goto S, Uchiyama S, et al. Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study. J Gastroenterol. 2014;49:814\u201324. https:\/\/doi.org\/10.1007\/s00535-013-0839-5.","journal-title":"J Gastroenterol"},{"key":"1229_CR254","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/jama.2019.8145","volume":"321","author":"H Watanabe","year":"2019","unstructured":"Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019;321:2414\u201327. https:\/\/doi.org\/10.1001\/jama.2019.8145.","journal-title":"JAMA"},{"key":"1229_CR255","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","volume":"7","author":"H Watanabe","year":"2022","unstructured":"Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial. JAMA Cardiol. 2022;7:407\u201317. https:\/\/doi.org\/10.1001\/jamacardio.2021.5244.","journal-title":"JAMA Cardiol"},{"key":"1229_CR256","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.122.012004","volume":"15","author":"Y Obayashi","year":"2022","unstructured":"Obayashi Y, Watanabe H, Morimoto T, Yamamoto K, Natsuaki M, Domei T, et al. Clopidogrel monotherapy after 1-month dual antiplatelet therapy in percutaneous coronary intervention: from the STOPDAPT-2 total cohort. Circ Cardiovasc Interv. 2022;15:e012004. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.122.012004.","journal-title":"Circ Cardiovasc Interv"},{"key":"1229_CR257","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4244\/AIJ-D-22-00033","volume":"9","author":"S Masuda","year":"2023","unstructured":"Masuda S, Muramatsu T, Ishibashi Y, Kozuma K, Tanabe K, Nakatani S, et al. Reduced-dose prasugrel monotherapy without aspirin after PCI with the SYNERGY stent in East Asian patients presenting with chronic coronary syndromes or non-ST-elevation acute coronary syndromes: rationale and design of the ASET Japan pilot study. AsiaIntervention. 2023;9:39\u201348. https:\/\/doi.org\/10.4244\/AIJ-D-22-00033.","journal-title":"AsiaIntervention"},{"key":"1229_CR258","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1253\/circj.CJ-23-0051","volume":"87","author":"T Muramatsu","year":"2023","unstructured":"Muramatsu T, Masuda S, Kotoku N, Kozuma K, Kawashima H, Ishibashi Y, et al. Prasugrel monotherapy after percutaneous coronary intervention with biodegradable-polymer platinum-chromium everolimus eluting stent for Japanese patients with chronic coronary syndrome (ASET-JAPAN). Circ J. 2023;87:857\u201365. https:\/\/doi.org\/10.1253\/circj.CJ-23-0051.","journal-title":"Circ J"},{"key":"1229_CR259","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-25-0356","author":"K Miyashita","year":"2025","unstructured":"Miyashita K, Muramatsu T, Revaiah PC, Nakazawa G, Ishibashi Y, Kozuma K, et al. Aspirin-free prasugrel monotherapy after percutaneous coronary intervention in patients with Non-ST elevation acute coronary syndrome. Circ J. 2025. https:\/\/doi.org\/10.1253\/circj.CJ-25-0356.","journal-title":"Circ J"},{"key":"1229_CR260","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2507980","author":"PO Guimaraes","year":"2025","unstructured":"Guimaraes PO, Franken M, Tavares CAM, Antunes MO, Silveira FS, Andrade PB, et al. Early withdrawal of aspirin after PCI in acute coronary syndromes. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2507980.","journal-title":"N Engl J Med"},{"key":"1229_CR261","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jacc.2023.10.013","volume":"83","author":"H Watanabe","year":"2024","unstructured":"Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Nishikawa R, et al. Clopidogrel vs aspirin monotherapy beyond 1 year after percutaneous coronary intervention. J Am Coll Cardiol. 2024;83:17\u201331. https:\/\/doi.org\/10.1016\/j.jacc.2023.10.013.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR262","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","volume":"82","author":"F Gragnano","year":"2023","unstructured":"Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, et al. P2Y(12) inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol. 2023;82:89\u2013105. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.051.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR263","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(25)01562-4","volume":"406","author":"M Valgimigli","year":"2025","unstructured":"Valgimigli M, Choi KH, Giacoppo D, Gragnano F, Kimura T, Watanabe H, et al. Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis. Lancet. 2025;406:1091\u2013102. https:\/\/doi.org\/10.1016\/S0140-6736(25)01562-4.","journal-title":"Lancet"},{"key":"1229_CR264","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1611594.","journal-title":"N Engl J Med"},{"key":"1229_CR265","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1708454.","journal-title":"N Engl J Med"},{"key":"1229_CR266","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","volume":"380","author":"RD Lopes","year":"2019","unstructured":"Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1817083.","journal-title":"N Engl J Med"},{"key":"1229_CR267","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","volume":"394","author":"P Vranckx","year":"2019","unstructured":"Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394:1335\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(19)31872-0.","journal-title":"Lancet"},{"key":"1229_CR268","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","volume":"40","author":"G Gargiulo","year":"2019","unstructured":"Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J. 2019;40:3757\u201367. https:\/\/doi.org\/10.1093\/eurheartj\/ehz732.","journal-title":"Eur Heart J"},{"key":"1229_CR269","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/CIRCULATIONAHA.118.036768","volume":"139","author":"Y Matsumura-Nakano","year":"2019","unstructured":"Matsumura-Nakano Y, Shizuta S, Komasa A, Morimoto T, Masuda H, Shiomi H, et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circulation. 2019;139:604\u201316. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.036768.","journal-title":"Circulation"},{"key":"1229_CR270","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","volume":"381","author":"S Yasuda","year":"2019","unstructured":"Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381:1103\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1904143.","journal-title":"N Engl J Med"},{"key":"1229_CR271","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5905022","volume":"2022","author":"D Fukamachi","year":"2022","unstructured":"Fukamachi D, Okumura Y, Matsumoto N, Tachibana E, Oiwa K, Ichikawa M, et al. Edoxaban monotherapy in nonvalvular atrial fibrillation patients with coronary artery disease. J Interv Cardiol. 2022;2022:5905022. https:\/\/doi.org\/10.1155\/2022\/5905022.","journal-title":"J Interv Cardiol"},{"key":"1229_CR272","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa2407362","volume":"391","author":"MS Cho","year":"2024","unstructured":"Cho MS, Kang DY, Ahn JM, Yun SC, Oh YS, Lee CH, et al. Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease. N Engl J Med. 2024;391:2075\u201386. https:\/\/doi.org\/10.1056\/NEJMoa2407362.","journal-title":"N Engl J Med"},{"key":"1229_CR273","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2507532","author":"G Lemesle","year":"2025","unstructured":"Lemesle G, Didier R, Steg PG, Simon T, Montalescot G, Danchin N, et al. Aspirin in patients with chronic coronary syndrome receiving oral anticoagulation. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2507532.","journal-title":"N Engl J Med"},{"key":"1229_CR274","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1253\/circrep.CR-22-0096","volume":"4","author":"Y Ozaki","year":"2022","unstructured":"Ozaki Y, Kawai H, Muramatsu T, Harada M, Takahashi H, Ishii H, et al. Rationale and design of rivaroxaban estimation with warfarin in atrial fibrillation Patients with coronary stent implantation (REWRAPS). Circ Rep. 2022;4:604\u20138. https:\/\/doi.org\/10.1253\/circrep.CR-22-0096.","journal-title":"Circ Rep"},{"key":"1229_CR275","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1056\/NEJMoa1907775","volume":"381","author":"SR Mehta","year":"2019","unstructured":"Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, et al. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2019;381:1411\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1907775.","journal-title":"N Engl J Med"},{"key":"1229_CR276","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamacardio.2020.1251","volume":"5","author":"KR Bainey","year":"2020","unstructured":"Bainey KR, Engstr\u00f8m T, Smits PC, Gershlick AH, James SK, Storey RF, et al. Complete vs culprit-lesion-only revascularization for ST-segment elevation myocardial infarction: a systematic review and meta-analysis. JAMA Cardiol. 2020;5:1\u20139. https:\/\/doi.org\/10.1001\/jamacardio.2020.1251.","journal-title":"JAMA Cardiol"},{"key":"1229_CR277","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/s0140-6736(15)60648-1","volume":"386","author":"T Engstrom","year":"2015","unstructured":"Engstrom T, Kelbaek H, Helqvist S, Hofsten DE, Klovgaard L, Holmvang L, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015;386:665\u201371. https:\/\/doi.org\/10.1016\/s0140-6736(15)60648-1.","journal-title":"Lancet"},{"key":"1229_CR278","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1056\/NEJMoa1701067","volume":"376","author":"PC Smits","year":"2017","unstructured":"Smits PC, Abdel-Wahab M, Neumann FJ, de Boxma- Klerk BM, Lunde K, Schotborgh CE, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J Med. 2017;376:1234\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1701067.","journal-title":"N Engl J Med"},{"key":"1229_CR279","doi-asserted-by":"publisher","first-page":"225","DOI":"10.4244\/eij-d-20-00012","volume":"16","author":"PC Smits","year":"2020","unstructured":"Smits PC, Laforgia PL, Abdel-Wahab M, Neumann FJ, Richardt G, Boxma-de Klerk B, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction: three-year follow-up with cost benefit analysis of the Compare-Acute trial. EuroIntervention. 2020;16:225\u201332. https:\/\/doi.org\/10.4244\/eij-d-20-00012.","journal-title":"EuroIntervention"},{"key":"1229_CR280","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJMoa2300468","volume":"389","author":"S Biscaglia","year":"2023","unstructured":"Biscaglia S, Guiducci V, Escaned J, Moreno R, Lanzilotti V, Santarelli A, et al. Complete or culprit-only PCI in older patients with myocardial infarction. N Engl J Med. 2023;389:889\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2300468.","journal-title":"N Engl J Med"},{"key":"1229_CR281","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1056\/NEJMoa2314149","volume":"390","author":"F Bohm","year":"2024","unstructured":"Bohm F, Mogensen B, Engstrom T, Stankovic G, Srdanovic I, Lonborg J, et al. FFR-guided complete or culprit-only PCI in patients with myocardial infarction. N Engl J Med. 2024;390:1481\u201392. https:\/\/doi.org\/10.1056\/NEJMoa2314149.","journal-title":"N Engl J Med"},{"key":"1229_CR282","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1056\/NEJMoa1701067","volume":"376","author":"PC Smits","year":"2017","unstructured":"Smits PC, Abdel-Wahab M, Neumann FJ, Boxma-de Klerk BM, Lunde K, Schotborgh CE, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J Med. 2017;376:1234\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1701067.","journal-title":"N Engl J Med"},{"key":"1229_CR283","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.jacc.2021.08.061","volume":"78","author":"G Rioufol","year":"2021","unstructured":"Rioufol G, Derimay F, Roubille F, Perret T, Motreff P, Angoulvant D, et al. Fractional flow reserve to guide treatment of patients with multivessel coronary artery disease. J Am Coll Cardiol. 2021;78:1875\u201385. https:\/\/doi.org\/10.1016\/j.jacc.2021.08.061.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR284","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104650","author":"E Puymirat","year":"2021","unstructured":"Puymirat E, Cayla G, Simon T, Steg PG, Montalescot G, Durand-Zaleski I, et al. Multivessel PCI guided by FFR or angiography for myocardial infarction. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2104650.","journal-title":"N Engl J Med"},{"key":"1229_CR285","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.123.013913","volume":"17","author":"E Puymirat","year":"2024","unstructured":"Puymirat E, Cayla G, Simon T, Steg PG, Montalescot G, Durand-Zaleski I, et al. Three-year outcomes with fractional flow reserve-guided or angiography-guided multivessel percutaneous coronary intervention for myocardial infarction. Circ Cardiovasc Interv. 2024;17:e013913. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.123.013913.","journal-title":"Circ Cardiovasc Interv"},{"key":"1229_CR286","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/eurheartj\/ehac763","volume":"44","author":"JM Lee","year":"2023","unstructured":"Lee JM, Kim HK, Park KH, Choo EH, Kim CJ, Lee SH, et al. Fractional flow reserve versus angiography-guided strategy in acute myocardial infarction with multivessel disease: a randomized trial. Eur Heart J. 2023;44:473\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehac763.","journal-title":"Eur Heart J"},{"key":"1229_CR287","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-023-03153-7","volume":"23","author":"M Barauskas","year":"2023","unstructured":"Barauskas M, Ziubryte G, Jodka N, Unikas R. Quantitative flow ratio vs. angiography-only guided PCI in STEMI patients: one-year cardiovascular outcomes. BMC Cardiovasc Disord. 2023;23:136. https:\/\/doi.org\/10.1186\/s12872-023-03153-7.","journal-title":"BMC Cardiovasc Disord"},{"key":"1229_CR288","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S0140-6736(23)00351-3","volume":"401","author":"R Diletti","year":"2023","unstructured":"Diletti R, den Dekker WK, Bennett J, Schotborgh CE, van der Schaaf R, Sabate M, et al. Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial. Lancet. 2023;401:1172\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(23)00351-3.","journal-title":"Lancet"},{"key":"1229_CR289","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1016\/j.jcin.2024.09.058","volume":"17","author":"WK den Dekker","year":"2024","unstructured":"den Dekker WK, Elscot JJ, Bennett J, Schotborgh CE, van der Schaaf R, Sabate M, et al. Timing of complete multivessel revascularization in acute coronary syndrome: 2-year results of the BIOVASC study. JACC Cardiovasc Interv. 2024;17:2866\u201374. https:\/\/doi.org\/10.1016\/j.jcin.2024.09.058.","journal-title":"JACC Cardiovasc Interv"},{"key":"1229_CR290","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1056\/NEJMoa2307823","volume":"389","author":"BE Stahli","year":"2023","unstructured":"Stahli BE, Varbella F, Linke A, Schwarz B, Felix SB, Seiffert M, et al. Timing of complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2023;389:1368\u201379. https:\/\/doi.org\/10.1056\/NEJMoa2307823.","journal-title":"N Engl J Med"},{"key":"1229_CR291","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.jacc.2018.07.089","volume":"72","author":"KS Rathod","year":"2018","unstructured":"Rathod KS, Koganti S, Jain AK, Astroulakis Z, Lim P, Rakhit R, et al. Complete versus culprit-only lesion intervention in patients with acute coronary syndromes. J Am Coll Cardiol. 2018;72:1989\u201399. https:\/\/doi.org\/10.1016\/j.jacc.2018.07.089.","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR292","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/eurheartj\/ehu338","volume":"36","author":"J Layland","year":"2015","unstructured":"Layland J, Oldroyd KG, Curzen N, Sood A, Balachandran K, Das R, et al. Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. Eur Heart J. 2015;36:100\u201311. https:\/\/doi.org\/10.1093\/eurheartj\/ehu338.","journal-title":"Eur Heart J"},{"key":"1229_CR293","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jcin.2024.01.278","volume":"17","author":"JJ Elscot","year":"2024","unstructured":"Elscot JJ, Kakar H, Scarparo P, den Dekker WK, Bennett J, Schotborgh CE, et al. Timing of complete multivessel revascularization in patients presenting with non-ST-segment elevation acute coronary syndrome. JACC Cardiovasc Interv. 2024;17:771\u201382. https:\/\/doi.org\/10.1016\/j.jcin.2024.01.278.","journal-title":"JACC Cardiovasc Interv"},{"key":"1229_CR294","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710261","author":"H Thiele","year":"2017","unstructured":"Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med. 2017. https:\/\/doi.org\/10.1056\/NEJMoa1710261.","journal-title":"N Engl J Med"},{"key":"1229_CR295","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1056\/NEJMoa1808788","volume":"379","author":"H Thiele","year":"2018","unstructured":"Thiele H, Akin I, Sandri M, de Waha-Thiele S, Meyer-Saraei R, Fuernau G, et al. One-year outcomes after PCI strategies in cardiogenic shock. N Engl J Med. 2018;379:1699\u2013710. https:\/\/doi.org\/10.1056\/NEJMoa1808788.","journal-title":"N Engl J Med"},{"key":"1229_CR296","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029792","volume":"12","author":"KH Choi","year":"2023","unstructured":"Choi KH, Yang JH, Park TK, Lee JM, Song YB, Hahn JY, et al. Culprit-only versus immediate multivessel percutaneous coronary intervention in patients with acute myocardial infarction complicating advanced cardiogenic shock requiring venoarterial-extracorporeal membrane oxygenation. J Am Heart Assoc. 2023;12:e029792. https:\/\/doi.org\/10.1161\/JAHA.123.029792.","journal-title":"J Am Heart Assoc"},{"key":"1229_CR297","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/eurheartj\/ehw149","volume":"38","author":"S Agewall","year":"2017","unstructured":"Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Caforio AL, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017;38:143\u201353. https:\/\/doi.org\/10.1093\/eurheartj\/ehw149.","journal-title":"Eur Heart J"},{"key":"1229_CR298","doi-asserted-by":"publisher","first-page":"e891","DOI":"10.1161\/CIR.0000000000000670","volume":"139","author":"JE Tamis-Holland","year":"2019","unstructured":"Tamis-Holland JE, Jneid H, Reynolds HR, Agewall S, Brilakis ES, Brown TM, et al. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association. Circulation. 2019;139:e891\u2013908. https:\/\/doi.org\/10.1161\/CIR.0000000000000670.","journal-title":"Circulation"},{"key":"1229_CR299","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1253\/circj.CJ-22-0779","volume":"87","author":"S Hokimoto","year":"2023","unstructured":"Hokimoto S, Kaikita K, Yasuda S, Tsujita K, Ishihara M, Matoba T, et al. JCS\/CVIT\/JCC 2023 Guideline focused update on diagnosis and treatment of vasospastic angina (coronary spastic angina) and coronary microvascular dysfunction. Circ J. 2023;87:879\u2013936. https:\/\/doi.org\/10.1253\/circj.CJ-22-0779.","journal-title":"Circ J"},{"key":"1229_CR300","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jjcc.2023.07.014","volume":"83","author":"J Takahashi","year":"2024","unstructured":"Takahashi J, Onuma S, Hao K, Godo S, Shiroto T, Yasuda S. Pathophysiology and diagnostic pathway of myocardial infarction with non-obstructive coronary arteries. J Cardiol. 2024;83:17\u201324. https:\/\/doi.org\/10.1016\/j.jjcc.2023.07.014.","journal-title":"J Cardiol"},{"key":"1229_CR301","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.114.011201","volume":"131","author":"S Pasupathy","year":"2015","unstructured":"Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circulation. 2015;131:861\u201370. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.011201.","journal-title":"Circulation"}],"container-title":["Cardiovascular Intervention and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-025-01229-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12928-025-01229-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-025-01229-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T06:02:37Z","timestamp":1773986557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12928-025-01229-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":301,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1229"],"URL":"https:\/\/doi.org\/10.1007\/s12928-025-01229-z","relation":{},"ISSN":["1868-4300","1868-4297"],"issn-type":[{"value":"1868-4300","type":"print"},{"value":"1868-4297","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}